[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fudan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":602},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,510,0,25,[9,44,63,90,114,133,158,179,205,225,252,280,300,320,346,367,385,409,434,461,484,505,535,559,583],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053563","phase-2-a-phase-ii-clinical-study-of-multimodal-ablation-combined-with-systemic-drug-therapy-for-advanced-solid-tumors-100053563",false,"NCT06889610","A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","A Single-center,Multi-cohort,Prospective Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","Inclusion Criteria i. Common eligibility criteria for all cohorts:\n\n1\\. Age between 18-80 years,gender not limited; 2. Patients with hepatic lesions amenable to ablation, all hepatic lesions \\\u003C5 cm in diameter; 3. Expected survival≥3 months; 4. ECOG performance status score of 0-1; 5. Within 14 days before the first dose,laboratory tests indicate adequate organ function:\n\na) Hematology:WBC≥3.0×10\\^9\u002FL;ANC≥1.5×10\\^9\u002FL;PLT≥75×10\\^9\u002FL;HGB≥90 g\u002FL b) Liver function:Child-Pugh score≤7,AST≤5.0×ULN;ALT≤5.0×ULN;TBIL≤1.5×ULN c) Renal function:Cr≤1.5×ULN or CrCl≥60 mL\u002Fmin d) Coagulation function:INR≤1.5×ULN(for patients on anticoagulant therapy,≤3×ULN,anticoagulants must be discontinued one week before ablation);APTT≤1.5×ULN ii. Additional eligibility criteria for each cohort:\n\n1. Colorectal Cancer：\n\n   a) Clinically or pathologically confirmed colorectal cancer with liver metastases that are unresectable, or the patient is intolerant to or refuses surgery; b) Patients who have failed standard second-line drug therapy.\n2. Triple-negative breast cancer :\n\n   1. Clinically or pathologically confirmed triple-negative breast cancer(triple-negative defined as\\\u003C1% nuclear staining for ER and PR expression and HER2 negative);\n   2. Patients who have failed standard second-line drug therapy(including those who have failed PD-1 monoclonal antibody therapy, with progression within six months of adjuvant or neoadjuvant therapy considered as first-line therapy failure).\n3. Melanoma :\n\n   1. Clinically or pathologically confirmed melanoma liver metastasis, with inoperable or intolerable liver lesions or refusal of surgical resection;\n   2. Patients who have failed standard first-line drug therapy.\n\nExclusion Criteria:\n\ni. Common exclusion criteria for all cohorts:\n\n1. Patients with known allergy or suspected allergy to the study drugs or similar drugs;\n2. Patients who have participated in another clinical study and received at least one treatment within 4 weeks prior to enrollment;\n3. History or concurrent presence of other malignant tumors(except for cured basal cell carcinoma of the skin,superficial bladder cancer,carcinoma in situ of the cervix,and papillary thyroid carcinoma);\n4. Patients with immunodeficiency diseases within 7 days prior to the first dose,or currently receiving systemic corticosteroid therapy(≥10mg\u002Fday prednisone or equivalent dose of other corticosteroids),or other forms of immunosuppressive therapy;\n5. Symptomatic central nervous system(CNS)metastases,or other evidence indicating that the CNS metastases have not been controlled,and deemed unsuitable for enrollment by the investigator;\n6. Patients who have previously undergone organ or bone marrow transplantation;\n7. Uncontrollable pleural effusion,pericardial effusion,or ascites causing respiratory syndrome(≥CTCAE grade 2 dyspnea);\n8. Esophageal(gastric fundus)variceal rupture bleeding within the last month;\n9. Other antitumor treatments outside the combined regimen,such as radiotherapy,systemic chemotherapy,etc.;\n10. Clinically significant electrolyte abnormalities as judged by the investigator;\n11. Insufficiency or failure of major organs;\n12. Patients who have received systemic drug therapy,radiotherapy,or local liver treatment,with a time interval of less than 1 month since the last systemic treatment or local liver treatment;\n13. Patients who have received immunotherapy and experienced grade 3 or higher immune-related adverse events(irAEs)(except for thyroid function abnormalities,blood sugar abnormalities);\n14. Active or uncontrolled severe infections(≥CTCAE grade 2 infections);\n15. Any other disease,clinically significant metabolic abnormalities,physical examination abnormalities,or laboratory test abnormalities that,in the investigator's judgment,may have a disease or condition that makes the patient unsuitable for the study drug,or may affect the interpretation of the study results,or may place the patient at high risk;\n16. Pregnant or breastfeeding women,or women of childbearing age with a positive baseline pregnancy test;\n17. Known human immunodeficiency virus(HIV)infection;known clinically significant liver disease history,including viral hepatitis\\[known carriers of hepatitis B virus(HBV)must exclude active HBV infection,i.e.,HBV DNA positive(\\>1×10\\^4 copies\u002FmL or\\>2000 IU\u002FmL);known hepatitis C virus(HCV)infection and HCV RNA positive(\\>1×10\\^3 copies\u002FmL),or other hepatitis,cirrhosis;\n18. Patients with severe heart,lung,liver,or kidney dysfunction,irreversible coagulation disorders,or other uncontrolled diseases(including hypertension or diabetes,active infections,mental illness,or social conditions that may affect patient compliance);\n19. Other factors that may affect patient safety or trial compliance as judged by the investigator.\n\nii. Additional exclusion criteria for each cohort:\n\n1. Colorectal Cancer :\n\n   a) Patients with uncontrolled hypertension, defined as: patients with hypertension that cannot be well-controlled with a single antihypertensive agent (SBP ≥150 mmHg or DBP ≥100 mmHg); or patients who require two or more antihypertensive medications to control blood pressure.\n\n   b）Patients with urine dipstick proteinuria ≥2+ and a 24-hour urinary protein level \\>1.0 g.\n\n   c）Patients with gastrointestinal diseases such as active gastric or duodenal ulcers, ulcerative colitis, or active bleeding from an unresected tumor; or other conditions judged by the investigator as potentially causing gastrointestinal bleeding or perforation.\n\n   d）Patients with evidence or history of a significant bleeding tendency within 3 months prior to enrollment (e.g., bleeding \\>30 mL, hematemesis, melena, hematochezia), hemoptysis (\\>5 mL of fresh blood within 4 weeks), or a thromboembolic event (including stroke and\u002For transient ischemic attack) within the past 12 months.\n\n   e）Patients with clinically significant cardiovascular disease, including but not limited to, acute myocardial infarction, severe\u002Funstable angina, or coronary artery bypass grafting within 6 months prior to enrollment.\n\n   f）Congestive heart failure of New York Heart Association (NYHA) class \\> II; ventricular arrhythmias requiring medication; or an ECG showing a QTc interval ≥480 milliseconds.\n\n   g）Patients who are unable to take fruquintinib orally.\n2. Triple-negative breast cancer :\n\n   a) Patients who have previously received pucotenlimab treatment;\n3. Melanoma :\n\n   1. Patients who have previously received pembrolizumab or toripalimab treatment;\n   2. Patients currently have uncontrolled hypertension,defined as:patients with hypertension that cannot be well controlled with monotherapy(systolic blood pressure≥150 mmHg,or diastolic blood pressure≥100 mmHg);or patients using two or more antihypertensive drugs to control blood pressure;\n   3. Urine routine indicates proteinuria≥2+,and 24-hour urine protein\\>1.0g;\n   4. Significant clinically meaningful cardiovascular diseases,including but not limited to acute myocardial infarction,severe\u002Funstable angina,or coronary artery bypass grafting within 6 months before enrollment;\n   5. Congestive heart failure New York Heart Association(NYHA)classification\\>2;ventricular arrhythmias requiring drug treatment;electrocardiogram(ECG)showing QTc interval≥480 milliseconds.","ALL","18 Years","80 Years",{"count":21,"type":22},95,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study focuses on the treatment of liver metastases from three common cancers: colorectal cancer, triple-negative breast cancer and melanoma. Currently, there are limitations in the treatment of liver metastases of these cancers. Multimodal thermophysical ablation therapy can reshape the tumor microenvironment, release neoantigens, and act as an in-situ vaccine. On this basis, the combination of multimodal ablation with immunotherapeutic drugs such as pucotenlimab will be explored. The efficacy and safety of this combination therapy in patients with liver metastases of solid tumors will be investigated, with the expectation of breaking through the existing treatment limitations.",[28,29,30],"Triple Negative Breast Cancer Metastatic","Melanoma Metastatic","Colorectal Cancer Metastatic","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2026-03-30",{"date":39,"type":22},"2028-12-30",{"name":41,"class":42},"Fudan University","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":43},"100053252","phase-2-an-open-label-bayesian-adaptive-phase-ii-clinical-study-in-hrher2--advanced-breast-cancer-after-progression-on-standard-therapy-100053252","NCT07117630","An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+\u002FHER2- Advanced Breast Cancer After Progression on Standard Therapy","Inclusion Criteria:\n\n* Women aged ≥ 18 years old.\n* Patients with histologically confirmed HR+\u002FHER2- invasive breast cancer (specific definition: ER \\> 10% tumor cell positivity by immunohistochemistry is defined as ER positive, PR positive, PR \\> 10% tumor cell positivity is defined as PR positive; HER2 0 - 1+ or HER2 ++ but negative by FISH without amplification is defined as HER2 negative).\n* Patients with HR+\u002FHER2- advanced breast cancer who have experienced disease progression after receiving systemic therapy including CDK4\u002F6 inhibitors and endocrine therapy.\n* Patients whom the investigator judges to be suitable for continued endocrine therapy\n* Patients with at least one measurable lesion per RECIST version 1.1 criteria (≥ 20 mm on conventional CT scan, ≥ 10 mm on spiral CT scan, and without prior radiotherapy for measurable lesion).\n* Patients whose main organs function normally by meeting the following requirements:\n* Hematology criteria: HB ≥ 90 g\u002FL (no blood transfusion within 14 days); ANC ≥ 1.5 × 109\u002FL; PLT ≥ 75 × 109\u002FL;\n* Blood chemistry criteria: TBIL ≤ 1.5 × ULN (upper limit of normal); ALT and AST ≤ 3 × ULN; if liver metastasis is present, then ALT and AST ≤ 5 × ULN; serum Cr ≤ 1× ULN, endogenous creatinine clearance \\> 50 mL\u002Fmin (Cockcroft-Gault formula);\n* Patients who have not received radiotherapy, molecular targeted therapy, or surgery within 3 weeks prior to the start of the study and have recovered from acute toxicities of prior therapies (if a surgery has been undergone, the wound has completely healed); patients who have no peripheral neuropathy or Grade I peripheral neurotoxicity;\n* Patients with ECOG score ≤ 2, and life expectancy ≥ 3 months;\n* Female subjects of childbearing potential are required to use a medically acceptable method of contraception during study treatment and for at least 3 months after the last dose of study drug;\n* Subjects will be enrolled in this study voluntarily, sign the informed consent form (ICF), have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* Patients who have received radiotherapy (except for palliative reasons), chemotherapy, immunotherapy, or bisphosphonates (except for bone metastases) within 3 weeks prior to treatment.\n* Patients with uncontrolled central nervous system metastases (defined as symptomatic or requiring the use of corticosteroids or mannitol to control symptoms).\n* Patients with a history of clinically important or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction within the past 6 months, or ventricular arrhythmia.\n* Patients with ongoing ARs ≥ Grade 1 due to prior therapy. Exception to this is alopecia or those that, in the opinion of the investigator, should not be excluded. Such cases should be clearly documented in the investigator's notes.\n* Patients who have undergone major surgery (except for minor outpatient surgery, such as placement of vascular access) within 3 weeks of the first course of study treatment.\n* Pregnant or lactating patients.\n* Patients with a history of malignancy (except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) within the past five years.\n* Inability to swallow, chronic diarrhea and intestinal obstruction, there are multiple factors affecting the taking and absorption of drugs.\n* Presence of a third space effusion (such as large pleural fluid and ascites) that cannot be controlled by drainage or other methods.\n* Long-term unhealed wounds or incompletely healed fractures.\n* Patients with known HBV or HCV infection active phase or hepatitis B DNA ≥ 500, or chronic phase with abnormal liver function.\n* Those with allergies, or those who are known to have a history of allergy to the drug components of this study.\n* For the Experimental: PARP inhibitor + Fulvestrant + Pioglitazone arm , patients with pathogenic germline BRCA1\u002F2 mutations.","FEMALE",{"count":52,"type":22},60,[25],"This is a prospective, Phase II, open-label, two-arm parallel study evaluating the efficacy and safety of combined treatment (L-Ornithine L-Aspartate, N-Acetylcysteine) with CDK4\u002F6 inhibitors and Fulvestrant in patients with HR-positive\u002FHER2-negative advanced breast cancer (ABC) who have progressed on prior standard therapy including CDK4\u002F6 inhibitors and endocrine therapy.",[56],"Breast Cancer",{"date":34,"type":35},{"date":59,"type":35},"2025-09-25",{"date":61,"type":22},"2027-12",{"name":41,"class":42},{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":73,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":43},"100053669","pd-1-inhibitors-combined-with-local-therapy-at-different-timings-in-oligometastatic-escc-100053669","NCT07697859","PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC","A Phase III Randomized Controlled Study Investigating the Combination of PD-1 Inhibitors With Local Therapy Administered at Distinct Treatment Timings Among Patients With Oligometastatic Esophageal Squamous Cell Carcinoma","ESO-shanghai31","Inclusion Criteria:\n\n1. An eastern cooperative oncology group (ECOG) score of 0-1.\n2. Histologically or cytologically confirmed diagnosis of esophageal squamous cell carcinoma.\n3. Genuine oligometastasis (without a history of polyme-tastatic disease).\n4. A total of four or fewer distant metastases, a maximum of three metastases in a single organ, and a maximum diameter of each metastatic lesion not exceeding 5 cm.\n5. Biopsy of a metastatic lesion, PET\u002FCT scan, and PD-L1 CPS (IHC 22C3) are not required but preferred.\n6. No history of anti-PD-1\u002FPD-L1 therapy. However, the following conditions are also eligible for inclusion: the use of anti-PD1\u002FPD-L1 during induction\u002Fneoadjuvant\u002F concurrent therapy, or the use of anti-PD1\u002FPD-L1 for maintenance therapy but not due to toxicity or disease progression interrupting anti-PD1\u002FPD-L1 treatment, and the interruption has lasted for more than 3 months.\n7. Adequate hematological, hepatic, renal, and coagula-tion function. Baseline laboratory tests required to assess eligibility, including ANC ≥ 1.5 × 10\\^9\u002FL, PLT ≥ 80 × 10\\^9\u002FL, Hb ≥85 g\u002FL, ALB ≥28 g\u002FL, TBIL ≤ 1.5 × ULN, ALT and AST ≤ 3 × ULN, Cr ≤ 1.5 × ULN or CrCl ≥40 mL\u002Fmin, FEV1 ≥ 1 L. (liver metastases ALT and AST ≤ 5 × ULN, liver or bone metastases AKP ≤ 5 × ULN).(9) Enrolled voluntarily and signed informed consent by the patient himself or his legal representative.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Lung V20 remains over 25%.\n3. Confirmed diagnosis or clinical suspicion of esophageal fistula.\n4. Recurrence in the irradiated field.\n5. Active infection requiring systemic therapy.\n6. Active autoimmune disease requiring systemic treat-ment in the past 2 years.\n7. Immunodeficiency diagnosis, systemic steroid therapy, or any immunosuppressive treatment within 7 days before the first study treatment dose.\n8. Patients with a known history of grade 3 or higher adverse events, which are unsuitable for Anti-PD-1 therapy or adverse events that have not recovered to ≤CTCAE grade 1 (except alopecia).\n9. Uncontrolled pleural effusion, pericardial effusion, or pelvic ascites requiring repeated drainage.\n10. Unable or rejection to receive Anti-PD-1 therapy or unable to comply with study requirements or follow-up schedule.(11) Inability to provide informed consent.\n\n    \\-",{"count":72,"type":22},354,"2 Years","OBSERVATIONAL","Although immunotherapy combined with chemotherapy has become the first-line standard regimen for advanced esophageal squamous cell carcinoma (ESCC) and improved clinical outcomes in advanced patients, the prognosis of patients with esophageal cancer remains unsatisfactory, with a 5-year overall survival rate below 20%. As an effective modality for local disease control, local radiotherapy has no established optimal sequencing schedule when combined with systemic therapy. The timing of radiotherapy intervention may directly affect treatment efficacy, treatment tolerance and quality of life of patients.\n\nSeveral studies have explored the impact of radiotherapy timing in oligometastatic ESCC, yet substantial limitations persist in current evidence, resulting in a lack of unified guideline recommendations and wide heterogeneity in clinical practice. Most existing investigations are retrospective or small-sample prospective studies with high heterogeneity in study design, patient population selection and treatment regimens, yielding inconsistent conclusions that cannot support consistent clinical consensus.\n\nTo clarify the impact of radiotherapy timing on clinical efficacy in oligometastatic esophageal cancer, the investigator designed the present clinical trial. This study aims to compare the efficacy and safety of concurrent radiotherapy versus sequential radiotherapy on the basis of immunochemotherapy among patients with oligometastatic ESCC, so as to fill the evidence gap in existing research.",[77],"Esophageal Squamous Cell Carcinoma (ESCC)",[79,80,81,82],"Esophageal Squamous Cell Carcinoma","Anti-PD-1","Oligometastatis","Radiotherapy","2026-07-09",{"date":34,"type":35},{"date":86,"type":22},"2026-07-15",{"date":88,"type":22},"2031-07-15",{"name":41,"class":42},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},"100599051","phase-2-comparing-18f-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis-100599051","NCT07079462","Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","A Prospective Randomized Controlled Study Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","Inclusion Criteria:\n\n* 1\\. Age of 18 years or older. 2. Peritoneal metastasis of colorectal cancer confirmed by histological or cytological examination (International Union Against Cancer 8th edition of colorectal cancer staging).\n\n  3\\. Progression after receiving standard first-line treatment before enrollment; but excluding any type of immunotherapy.\n\n  4\\. Eastern Cooperative Oncology Group (ECOG) score of 0-1, with an expected survival time of more than 6 months.\n\n  5\\. ECOG score of 0-1. 6. Expected survival time of ≥ 24 weeks. 7. Laboratory tests for bone marrow, liver and kidney organ functions and coagulation function within 7 days before the first administration were in compliance with the study requirements (no blood transfusion, blood products, use of granulocyte colony-stimulating factor or other hematopoietic stimulating factors for correction within 7 days before the laboratory tests).\n\n  8\\. Women with reproductive capacity must have a negative blood pregnancy test result within 7 days before the first administration. Male or female patients with reproductive capacity voluntarily use effective contraceptive methods during the study period and within 6 months after the last study medication, such as double barrier contraceptive methods, condoms, oral or injectable contraceptive drugs, intrauterine devices, abstinence, etc. All female patients will be considered to have reproductive capacity, unless the female patient has naturally menopause, artificial menopause or sterilization (uterus removal, bilateral ovary removal).\n\n  9\\. Voluntary enrollment and signing of informed consent form, following the trial treatment plan and visit schedule.\n\nExclusion Criteria:\n\n* 1\\. Absolute neutrophil count (ANC) \\\u003C 1.5 × 109\u002FL, or platelet count \\\u003C 100 × 109\u002FL (for patients with liver metastasis, platelet count \\\u003C 80 × 109\u002FL), or hemoglobin \\\u003C 9 g\u002FdL; blood transfusion within 2 weeks prior to enrollment is not allowed to meet the inclusion criteria.\n\n  2\\. Serum total bilirubin \\> 1.5 times the upper limit of normal (ULN); for patients with liver metastasis, \\> 2.5 times ULN.\n\n  3\\. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\> 2.5 times ULN, or for patients with liver metastasis, ALT and\u002For AST \\> 5 times ULN.\n\n  4\\. Serum creatinine \\> 1.5 times ULN, or creatinine clearance rate \\\u003C 50 ml\u002Fmin (calculated according to the Cockcroft-Gault formula).\n\n  5\\. Partial thromboplastin time (APTT) or prothrombin time (PT) \\> 1.5 times ULN (based on the normal values of the clinical trial center).\n\n  6\\. The researcher determines clinically significant severe electrolyte abnormalities.\n\n  7\\. Urine protein test of 2+ or above, or 24-hour urine protein quantification ≥ 1.0 g\u002F24h.\n\n  8\\. Hypertension that is not well controlled by medication, defined as: systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg.\n\n  9\\. The patient currently has active peptic ulcer, ulcerative colitis, or other digestive tract diseases or active bleeding from an unresected tumor, or the researcher determines that it may cause gastrointestinal bleeding or perforation; or if there was a previous gastrointestinal perforation or gastrointestinal fistula, and the patient has not recovered after surgical treatment.\n\n  10\\. Within 6 months before enrollment, there is a history of arterial thrombosis or deep vein thrombosis, or within 2 months before enrollment, there is evidence or history of bleeding tendency or history of bleeding, regardless of severity.\n\n  11\\. Within 12 months before enrollment, a stroke event or transient ischemic attack occurred.\n\n  12\\. Within 6 months before enrollment, heart disease including congestive heart failure, acute myocardial infarction, severe\u002Funstable angina pectoris or coronary artery bypass surgery; or NYHA class 2 or above heart dysfunction patients; left ventricular ejection fraction (LVEF) \\\u003C 50%.\n\n  13\\. Uncontrolled malignant pleural effusion, ascites or pericardial effusion (defined as not being effectively controlled by diuretics or puncture as determined by the researcher).\n\n  14\\. Any patient who has received any anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody (or any other antibody acting on the T cell co-stimulation or checkpoint pathways) before enrollment.\n\n  15\\. Within 4 weeks before enrollment, received any form of radiotherapy. 16. At the screening stage, there is a clinically detectable second primary malignant tumor, or other malignant tumors occurred in the past 5 years, excluding fully treated non-melanoma skin cancer, cervical carcinoma in situ and superficial bladder tumor \\[non-invasive tumors, carcinoma in situ and T1 (tumor invasion of the lamina propria)\\], if present.\n\n  17\\. Known clinical significance of liver disease history, including but not limited to known hepatitis B virus (HBV) infection and positive HBV DNA (≥ 1 × 104\u002Fml); known hepatitis C virus (HCV) infection and positive HCV RNA (≥ 1 × 103\u002Fml), or liver cirrhosis, etc.\n\n  18\\. Pregnant or lactating women or women with a possibility of pregnancy who have a positive pregnancy test before the first medication; or female participants who are unwilling to implement strict contraception during the study.\n\nThe researcher considers that the subject has any clinical or laboratory abnormalities or non-compliance issues that make them unsuitable to participate in this clinical study.",{"count":98,"type":22},40,[25],"Main objective:\n\n1\\. To compare the objective response rate (ORR) of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cabozantinib and second-line standard treatment in the treatment of peritoneal metastasis of colorectal cancer.\n\nSecondary objectives:\n\n1. To compare the disease control rate (DCR), duration of continuous remission (DoR), progression-free survival (PFS) and overall survival (OS) of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cabozantinib and second-line standard treatment in the treatment of peritoneal metastasis of colorectal cancer.\n2. To evaluate the safety and tolerability of 18F-FAPI PET-guided abdominal region radiotherapy combined with second-line standard treatment versus cabozantinib.",[102,103,104],"Colorectal Cancer","Peritoneal (Metastatic) Cancer","FAPI PET","2026-06-30",{"date":107,"type":35},"2026-07-02",{"date":109,"type":35},"2024-08-07",{"date":111,"type":22},"2028-01-31",{"name":41,"class":42},2,{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":43},"100421341","observational-prospective-study-of-immune-checkpoint-inhibitors-for-solid-neoplasms-100421341","NCT04766515","Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms","Multicenter Observational Prospective Study of Immune Checkpoint Inhibitors in Patients With Solid Neoplasms","Inclusion Criteria:\n\n* Age at least 18 years.\n* Pathologically confirmed diagnosis of a solid tumor cancer.\n* Patients receiving treatment with immune checkpoint inhibitors.\n* Ability to understand and willingness to provide the informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Patients with hematological malignancies or solid benign tumors.\n* Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.",{"count":122,"type":22},6000,"This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.",[125],"Cancer","2026-06-28",{"date":105,"type":35},{"date":129,"type":35},"2020-09-01",{"date":131,"type":22},"2027-08-30",{"name":41,"class":42},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":157,"locationsCount":43},"100476090","phase-2-neoadjuvant-radiation-in-locally-advanced-breast-cancer-100476090","NCT05479409","Neoadjuvant Radiation in Locally Advanced Breast Cancer","Effect of Neoadjuvant Radiation and Prediction of Response to Treatment in Locally Advanced Breast Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced breast carcinoma\n* Inoperable with with 4-6 courses of prior chemotherapy\n* No contradiction of radiation or chemo-radiotherapy\n* Patients should have the ability to understand and the willingness to sign a written informed consent document\n* Signed informed consent must be obtained prior to any study specific procedures\n\nExclusion Criteria:\n\n* Other prior or concurrent malignancy except adequately treated squamous cell or basal cell skin cancer or contralateral breast DCIS\n* Coagulation disorders\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and cardiac arrhythmia\n* Serious underlying medical illness with life expectancy less than 2 years.\n* Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.","70 Years",{"count":142,"type":22},70,[25],"The purpose of this study is to evaluate the efficacy and safety of neoadjuvant radiation therapy in improving local-regional control and facilitating surgical conversion in patients with inoperable locally advanced breast cancer after 2-6 courses of neoadjuvant chemotherapy. This study will also investigate whether beta-alanine supplementation and spatially fractionated radiotherapy can enhance the therapeutic response to neoadjuvant chemoradiotherapy. In addition, this study aims to explore tumor microenvironmental features and molecular biomarkers associated with treatment response, radioresistance, immune activation, and long-term outcomes.",[146],"Breast Neoplasms",[148,149,150],"breast cancer","neoadjuvant radiotherapy","biomarkers","2026-06-23",{"date":153,"type":35},"2026-06-26",{"date":155,"type":35},"2021-03-01",{"date":61,"type":22},{"name":41,"class":42},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":43},"100644196","phase-2-a-phase-ii-clinical-study-of-the-efficacy-and-safety-of-culmerciclib-rechallenge-in-hr-positive-her2-negative-breast-cancer-patients-with-resistance-to-first-line-endocrine-therapy-100644196","NCT07666555","A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.","A Phase II Clinical Trial Evaluating the Efficacy and Safety of Culmerciclib Combined With Fulvestrant Compared to an Investigator-Selected CDK4\u002F6 Inhibitor Combined With Fulvestrant in Patients With HR-Positive, HER2-Negative Breast Cancer Who Have Progressed After First-Line Endocrine Therapy","Inclusion Criteria:\n\n* 1\\) Female, ≥18 years old; ≤ 75years old 2)ECOG score 0-2; 3) Predicted survival ≥3 months;Patients with locally advanced and\u002For metastatic breast cancer confirmed by histopathology with positive ER expression and negative HER2 expression; 5) Enrolled subjects must meet one of the following criteria regarding prior endocrine therapy: i) Received CDK4\u002F6 inhibitor combined with endocrine therapy as adjuvant endocrine therapy, experienced recurrence or progression during or within 1 year after completion of adjuvant CDK4\u002F6 inhibitor therapy, and did not receive subsequent endocrine therapy; ii) Recurrence or progression more than 1 year after completion of adjuvant endocrine monotherapy, followed by progression after receiving CDK4\u002F6 inhibitor combined with endocrine therapy as first-line salvage endocrine therapy; iii) Newly diagnosed locally advanced or metastatic disease, with disease progression after receiving CDK4\u002F6 inhibitor combined with endocrine therapy as first-line salvage endocrine therapy; 6)Participants with recurrent or metastatic disease may receive rescue chemotherapy, ADC, or rescue endocrine therapy not exceeding first-line treatment; 7) The time interval between non-endocrine therapy should be ≥2 weeks; 8) At least one extracranial measurable lesion as defined by RECIST V1.1 criteria; 9) The functions of vital organs meet the requirements; 10) Fertile subjects must have a negative pregnancy test 7 days before starting treatment and must use an appropriate contraceptive method during treatment and for three months after completion of treatment; 11) The patient is fully informed and voluntarily signs the informed consent.\n\nExclusion Criteria:\n\n* 1\\) Previously diagnosed with HER2-positive breast cancer based on pathological testing; ; 2) Known allergy to the tested drug component; 3) inflammatory breast cancer at the time of screening; 4) pia meningeal metastasis confirmed by MRI or lumbar puncture; 5) Central nervous system metastasis confirmed by imaging; 6) To the best of the investigator's judgment, symptomatic visceral disease or any disease load or none is considered optimal Endocrine therapy options are not suitable for endocrine therapy; 7) Inability or unwillingness to swallow medication or receive intramuscular injections; 8) Gastrointestinal insufficiency or gastrointestinal disease (if not controlled) that may significantly affect study drug absorption Ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small intestine resection, etc.; 9) Patients with ascites, pleural effusion and pericardial effusion accompanied by clinical symptoms in the baseline period need drainage, or use it for the first time Patients with serous cavity drainage within 4 weeks before medication; 10) A history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency conditions, Or have a history of organ transplantation; 11) Other malignancies (cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and Thyroid cancer is excluded); 12) had undergone major surgical procedures or significant trauma within 4 weeks prior to the start of treatment, or was expected to undergo major surgery Surgical treatment; 13) Concomitant diseases that, in the investigator's judgment, seriously endanger patient safety or interfere with patient completion of the study (e.g.\n\nSevere hypertension, diabetes, thyroid disease, co-active hepatitis B\u002FC, and other activities Sexual infection); 14) Inability to understand or follow research instructions and requirements; 15) The researcher decides that it is not suitable to participate in this study","75 Years",{"count":167,"type":22},98,[25],"To evaluate the efficacy and safety of Culmerciclib combined with fulvestrant compared with investigator-selected CDK4\u002F6 inhibitors combined with fulvestrant in patients with HR-positive\u002FHER2-negative breast cancer who have progressed after first-line endocrine therapy",[56],"2026-06-22",{"date":173,"type":35},"2026-06-24",{"date":175,"type":22},"2026-06-06",{"date":177,"type":22},"2029-12-30",{"name":41,"class":42},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":140,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100643891","phase-3-an-open-label-randomized-phase-iii-study-of-trastuzumab-rezetecan-with-or-without-bevacizumab-in-first-to-third-line-blis-subtype-tnbc-100643891","NCT07669610","An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC","A Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab as First- to Third-Line Treatment for Basal-like Immune-suppressed Triple-Negative Breast Cancer","TRIBE","Inclusion Criteria:\n\n1. Female patients aged ≥18 years and ≤70 years;\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;\n3. Life expectancy of at least 3 months;\n4. Histologically confirmed invasive triple-negative breast cancer (defined as breast cancer with estrogen receptor \\[ER\\], progesterone receptor \\[PR\\], and human epidermal growth factor receptor 2 \\[HER-2\\] all determined to be negative by pathological testing. Specifically: ER-negative: IHC \\\u003C1%; PR-negative: IHC \\\u003C1%; HER2-negative: IHC -\u002F+ or IHC ++ with FISH\u002FCISH negative. All specimens must be verified as the BLIS subtype of the Fudan quadruple molecular classification by the Precision Medicine Center\u002FDepartment of Pathology at the study's participating center);\n5. Tumor stage: recurrent or metastatic breast cancer; for locally recurrent disease, radical surgical resection must be confirmed by the investigator to be not feasible. Number of prior lines of therapy in the advanced setting ≤2;\n6. Patients must have at least one lesion (measurable and\u002For non-measurable) that has not been previously irradiated, can be accurately assessed at baseline by CT\u002FMRI, and can be repeatedly evaluated according to RECIST 1.1;\n7. Adequate major organ function, meeting the following criteria:\n\n   Hematological parameters: hemoglobin (HB) ≥90 g\u002FL (without blood transfusion within 14 days); absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL; platelet count (PLT) ≥75×10⁹\u002FL;Biochemical parameters: total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN; in the presence of liver metastases, ALT and AST ≤5×ULN; serum creatinine (Cr) ≤1×ULN, and calculated creatinine clearance \\>50 mL\u002Fmin (Cockcroft-Gault formula);\n8. No prior radiotherapy, endocrine therapy, molecular targeted therapy, or surgery within 3 weeks before study initiation, and recovery from acute toxicities of prior treatment (if surgery was performed, the wound must be completely healed); no peripheral neuropathy or only grade I peripheral neurotoxicity;\n9. Female subjects of childbearing potential must agree to use a medically accepted contraceptive method during the study treatment period and for at least 3 months after the last dose of study drug;\n10. Subjects must voluntarily participate in this study, sign the informed consent form, have good compliance, and be willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n* Patients with any of the following criteria will be excluded from this study:\n\n  1. Known central nervous system (CNS) metastases or a history of CNS metastases prior to screening. For patients with clinically suspected CNS metastases, contrast-enhanced CT or contrast-enhanced magnetic resonance imaging (MRI) must be performed within 28 days before the first dose to rule out CNS metastases;\n  2. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure, angina pectoris, myocardial infarction within the past 6 months, or ventricular arrhythmias;\n  3. Persistent adverse events of Grade ≥1 resulting from prior treatment. Exceptions to this are alopecia or conditions that the investigator deems should not preclude enrollment. Such cases should be clearly documented in the investigator's notes;\n  4. Major surgery (excluding minor procedures such as placement of vascular access) within 3 weeks before the first cycle of study treatment;\n  5. Pregnant or lactating patients;\n  6. Other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin;\n  7. Presence of third-space fluid accumulation (e.g., massive pleural effusion or ascites) that cannot be controlled by drainage or other methods;\n  8. Participation in another anti-tumor drug clinical trial within 3 weeks before the first use of the study drug;\n  9. Long-term unhealed wounds or incompletely healed fractures;\n  10. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, or HBV DNA ≥500 IU\u002FmL, or chronic hepatitis with abnormal liver function;\n  11. History of allergic constitution, known allergy to any component of the study drug regimen, or history of allergy to other monoclonal antibodies;\n  12. History of gastrointestinal bleeding within the past 6 months, or clear evidence of a tendency for gastrointestinal bleeding, such as esophageal varices at risk of bleeding, active local ulcerative lesions, or fecal occult blood test ≥ (++). Patients with fecal occult blood test (+) should undergo gastroscopy;\n  13. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to study enrollment;\n  14. Urinalysis showing urine protein ≥ (++), or confirmed 24-hour urine protein quantification \\>1.0 g;\n  15. Hypertension that cannot be controlled to within normal range with antihypertensive medication (systolic blood pressure \\>140 mmHg, diastolic blood pressure \\>90 mmHg);\n  16. Prior use of anti-angiogenic agents or prior exposure to an antibody-drug conjugate (ADC) with a topoisomerase I inhibitor as the payload",{"count":188,"type":22},140,[190],"PHASE3","This study is a prospective, open-label, phase III, randomized controlled clinical trial. It is planned to screen patients with inoperable locally advanced or metastatic triple-negative breast cancer of the BLIS subtype. A total of 140 patients are planned to be enrolled.",[56,193],"Triple Negative Breast Cancer (TNBC)",[195],"triple negative breast cancer","NOT_YET_RECRUITING","2026-06-20",{"date":199,"type":35},"2026-06-25",{"date":201,"type":22},"2026-10-01",{"date":203,"type":22},"2029-03-30",{"name":41,"class":42},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":165,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":43},"100644324","phase-2-iparomlimab-and-tovorilimab-ql1706-combined-with-bevacizumab-and-chemotherapy-as-neoadjuvant-therapy-for-advanced-ovarian-cancer-100644324","NCT07663513","Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer","Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer: A Prospective, Single-Arm, Phase II Study","Inclusion Criteria:\n\n* Female, aged 18-75 years.\n* Histologically confirmed high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal adenocarcinoma.\n* FIGO stage III-IV unresectable ovarian cancer.\n* Life expectancy ≥16 weeks.\n* No prior anti-tumor therapy, including radiotherapy, chemotherapy, targeted therapy, or immunotherapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Adequate organ function, with laboratory test results meeting the following requirements:Hemoglobin (Hb) ≥90 g\u002FL; Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL; Platelet count (PLT) ≥100×10⁹\u002FL; Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (or ≤5×ULN in patients with liver metastases); Serum creatinine clearance (CrCl) \\>50 mL\u002Fmin (calculated using the Cockcroft-Gault formula); Coagulation function: international normalized ratio (INR) ≤1.5×ULN and activated partial thromboplastin time (APTT) ≤1.5×ULN.\n* The subject agrees to use effective contraceptive measures from the signing of the informed consent form until 120 days after the last dose of the study drug. Female subjects of childbearing potential (15-49 years) must have a negative urine pregnancy test within 7 days before the start of treatment and must not be lactating. A female patient is considered to be of childbearing potential if she has menstruated, has not reached a postmenopausal state (defined as ≥12 consecutive months of amenorrhea for reasons other than menopause), and has not undergone sterilization surgery (e.g., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).\n* No contraindications for surgery.\n* The subject voluntarily participates in this study, signs the informed consent form, is compliant with the protocol, and cooperates with follow-up.\n\nExclusion Criteria:\n\n* Non-epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (e.g., germ cell tumors), as well as ovarian tumors of low malignant potential (e.g., borderline ovarian tumors).\n* Prior immunotherapy, including immune checkpoint inhibitory antibodies (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies, etc.), immune checkpoint agonistic antibodies (e.g., anti-ICOS, anti-CD40, anti-CD137, anti-GITR, anti-OX40 antibodies, etc.), and immune cell therapy.\n* Known hypersensitivity to large molecule protein preparations. Contraindications or allergy to any component of iparomlimab and tovorilimab (QL1706), paclitaxel, or carboplatin.\n* Major surgery (excluding diagnostic laparoscopy; local surgical treatment of isolated lesions is acceptable) within 28 days before the first dose.\n* History of allogeneic tissue\u002Fsolid organ transplantation.\n* Presence of a condition requiring systemic corticosteroids (\\>10 mg prednisone equivalent per day) or other immunosuppressive agents (e.g., cyclophosphamide, azathioprine, methotrexate, thalidomide, TNF-α inhibitors, etc.) within 2 weeks before the first dose. Topical corticosteroids, nasal sprays, and inhaled steroids are permitted. Systemic corticosteroids for the prevention of contrast media allergy are allowed.\n* Active or potentially recurrent autoimmune disease, with the following exceptions: vitiligo, alopecia, psoriasis, or eczema not requiring systemic treatment; hypothyroidism due to autoimmune thyroiditis requiring only stable hormone replacement therapy; type I diabetes mellitus requiring only stable insulin replacement therapy.\n* Other active malignancies within the past 5 years, except for locally curable cancers that have been cured (e.g., basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast), and breast cancer that has not recurred for \\>3 years after radical surgery.\n* History of interstitial lung disease and\u002For pneumonitis, or pulmonary hypertension.\n* Symptomatic, untreated, or clinically unstable brain metastases or leptomeningeal metastases.\n* Hypertension (systolic blood pressure \\>150 mmHg and\u002For diastolic blood pressure \\>100 mmHg) or diabetes that remains poorly controlled despite standard treatment; uncontrolled or symptomatic arrhythmia.\n* Thromboembolic events (e.g., cerebrovascular accident, including transient ischemic attack, cerebral hemorrhage, cerebral infarction, or pulmonary embolism) within 6 months before the start of study treatment.\n* Myocardial infarction, severe\u002Funstable angina pectoris, or symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] class III or IV) within the past 12 months.\n* HIV-positive patients; HBsAg-positive with HBV DNA ≥2000 IU\u002FmL or ≥10⁴ copies\u002FmL; HCV antibody-positive with detectable HCV RNA.\n* Participation in another clinical trial within the previous 60 days or during the study treatment period.\n* Any other condition that, in the investigator's judgment, may interfere with the conduct of the study or the interpretation of the results. Other circumstances deemed by the investigator to make the patient unsuitable for enrollment.",{"count":213,"type":22},36,[25],"This is a single-center, single-arm clinical study to evaluate the efficacy and safety of iparomlimab and tovorilimab (QL1706) combined with paclitaxel, carboplatin, and bevacizumab as neoadjuvant therapy for advanced ovarian cancer.",[217],"Ovarian Cancers","2026-06-17",{"date":151,"type":35},{"date":221,"type":22},"2026-07",{"date":223,"type":22},"2029-04",{"name":41,"class":42},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":23,"phases":235,"briefSummary":236,"conditions":237,"keywords":242,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":249,"leadSponsor":251,"locationsCount":43},"100644360","phase-2-sacituzumab-tirumotecan-vs-mmae-adcs-in-advanced-urothelial-carcinoma-fuscc-spare-uc-01-100644360","NCT07662863","Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)","A Randomized, Open-label, Phase II Study Evaluating the Neurotoxicity and Efficacy of Sacituzumab Tirumotecan (Sac-TMT) Versus MMAE-based ADCs in Patients With Advanced Urothelial Carcinoma: The SPARE-UC-01 Trial","SPARE-UC-01","Inclusion Criteria\n\n1. Must voluntarily sign the written Institutional Review Board (IRB)\u002FEthics Committee (EC) approved informed consent form (ICF) prior to any screening procedures.\n2. Age \\> 18 years at the time of signing the ICF.\n3. Histologically or cytologically confirmed locally advanced (unresectable) or metastatic urothelial carcinoma (UC), including bladder, ureter, renal pelvis, or urethra. Participants with mixed histology are eligible provided that UC is the predominant component (\\> 50%).\n4. Must have received at least one prior line of systemic therapy for locally advanced or metastatic UC (e.g., Enfortumab Vedotin plus Pembrolizumab, Disitamab Vedotin plus Toripalimab, platinum-based chemotherapy, immune checkpoint inhibitors, Nectin-4 ADCs, HER2 ADCs, FGFR inhibitors, or other palliative chemotherapy regimens).\n5. Neuropathy Status:\n\n   Cohort A\u002FB: Baseline peripheral neuropathy (PN) Grade 0-1 (per NCI-CTCAE v5.0) with stable nerve function confirmed by Nerve Conduction Study (NCS) during screening.\n\n   Cohort C (Observational): Baseline PN Grade 2, or a history of PN \\> Grade 2 where the investigator deems the patient unsuitable for MMAE-based ADC treatment.\n6. At least one measurable lesion per RECIST v1.1. (Lesions in previously irradiated areas are considered target lesions only if clear progression is documented after radiotherapy).\n7. ECOG Performance Status of 0 or 1 at screening.\n8. Expected survival \\> 3 months.\n9. Must have adequate organ and bone marrow function (no blood transfusion, growth factors, or albumin support within 14 days prior to screening):\n\n   * Hematological: ANC \\>= 1.5 x 10\\^9\u002FL; Platelets \\>= 75 x 10\\^9\u002FL; Hemoglobin \\>= 90 g\u002FL.\n   * Hepatic: ALT and AST \\\u003C= 2.5 x ULN (or \\\u003C= 5 x ULN for patients with liver metastases); Total Bilirubin \\\u003C= 1.5 x ULN (if Total Bilirubin \\> 1.5 x ULN, Direct Bilirubin must be \\\u003C= ULN).\n   * Coagulation: INR \\\u003C= 1.5; APTT \\\u003C= 1.5 x ULN; PT \\\u003C ULN + 4 seconds.\n   * Renal: Creatinine Clearance (CrCl) \\>= 30 mL\u002Fmin, or Serum Creatinine \\\u003C= 1.5 x ULN.\n\nExclusion Criteria\n\n1. Prior treatment with TROP2-targeted ADCs, topoisomerase I inhibitors (e.g., irinotecan, topotecan), or ADCs containing topoisomerase I inhibitor payloads.\n2. Patients previously treated with both Enfortumab Vedotin (EV) and Disitamab Vedotin (DV) are excluded from Cohorts A and B (eligible for Cohort C only).\n3. Treatment with any investigational anti-tumor agents, chemotherapy, immunotherapy, monoclonal antibodies, targeted therapy, or radical radiotherapy within 2 weeks or 5 half-lives (whichever is shorter) prior to the first dose. Major surgery within 4 weeks prior to the first dose.\n4. Active CNS or meningeal metastases. Patients with previously treated CNS metastases are eligible if clinically stable for ≥ 4 weeks, off systemic corticosteroids for ≥ 2 weeks (physiological replacement ≤ 10 mg\u002Fday prednisone equivalent is allowed), and no evidence of radiographic progression.\n5. History of non-infectious pneumonitis\u002Finterstitial lung disease (ILD) requiring steroids. Current ILD or suspected ILD on screening chest CT (even if asymptomatic). Severe COPD, severely impaired lung function, or requirement for long-term oxygen therapy.\n6. QTcF interval \\> 470 ms (females) or \\> 450 ms (males). Within 6 months prior to the first dose: myocardial infarction, unstable angina, severe arrhythmia requiring intervention, uncontrolled hypertension, stroke, or TIA. NYHA Class III or IV congestive heart failure.\n7. Active keratitis, corneal ulcer, or severe dry eye syndrome.\n8. Active Hepatitis B (HBsAg positive and HBV-DNA \\> 2000 IU\u002FmL; patients with lower HBV-DNA must receive antiviral therapy); Active Hepatitis C (HCV antibody and RNA positive); Known HIV infection; Severe infection requiring IV antibiotics within 2 weeks prior to first dose.\n9. Hypersensitivity: Known severe hypersensitivity to sac-TMT, EV, DV, or their excipients.\n10. Any severe or uncontrolled systemic disease that, in the investigator's opinion, increases the risk to the participant.\n11. HbA1c ≥ 8% (Patients with well-controlled blood glucose, fasting glucose ≤ 10 mmol\u002FL, and investigator approval are eligible).\n12. History of allogeneic stem cell transplant or solid organ transplant.\n13. Pregnant or breastfeeding females.",{"count":234,"type":22},75,[25],"The main goal of this clinical trial is to learn if a new targeted cancer drug called sacituzumab tirumotecan (sac-TMT) works to treat cancer while causing less nerve damage in patients with advanced urothelial carcinoma who have progressed on or could not tolerate previous treatment such as enfortumab vedotin plus pembrolizumab (EVP) or disitamab vedotin plus toripalimab (DVT).\n\nThe main question it aims to answer is: Does sac-TMT lower the risk of getting severe nerve damage, as measured together by doctors, machines, and the participants?\n\nResearchers will compare sac-TMT to alternative MMAE-based ADC drugs (switching to a different MMAE-based ADC after the first one stopped working) to see if sac-TMT causes less nerve damage while still effectively treating the cancer. A small group of participants who had to stop their previous MMAE-based ADC treatment because of nerve damage will also receive sac-TMT to learn if the drug is safe for their nerves.\n\nParticipants will:\n\n1. Receive either sac-TMT or another MMAE-based ADC drug\n2. Have regular physical exams by a doctor to check their nerves\n3. Have machine tests to measure how well their nerves work\n4. Answer survey questions about their pain, numbness, and daily activities",[238,239,240,241],"Bladder Cancer","Metastatic Urothelial Carcinoma","Urothelial Carcinoma","Peripheral Neuropathy",[241,243,244,245,246],"Sacituzumab Tirumotecan","Enfortumab Vedotin","MMAE","Disitamab Vedotin",{"date":151,"type":35},{"date":86,"type":22},{"date":250,"type":22},"2029-12-01",{"name":41,"class":42},{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":140,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":267,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":43},"100641571","phase-2-study-of-radiotherapy-combined-with-platinum-adebrelimab-and-bevazumab-in-the-treatment-of-tnbc-bm-100641571","NCT07638852","Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.","A Prospective, Single-arm, Multi-centre, Phase II Clinical Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of Patients With Brain Metastasis of Triple Negativebreast Cancer","ABC-R","Inclusion Criteria:\n\n1. Age ≥18 years and ≤70 years, gender not limited;\n2. ECOG score 0-2;\n3. Pathologically confirmed HR-negative\u002FHER2-negative breast cancer patients with evidence of local recurrence or metastasis, unsuitable for curative surgical resection or radiotherapy; HR-negative is defined as ER-negative and PR-negative, with positive tumor cells accounting for \\\u003C10% of all tumor cells;\n4. Must not have previously used platinum-based drugs, or must have previously used platinum-based drugs (cisplatin or carboplatin and only one regimen) and meet the following definition of platinum sensitivity: no progression during at least 4 cycles of platinum-based therapy, and subsequent disease progression occurring more than 3 months after the last platinum-based therapy;\n5. Expected survival ≥8 weeks;\n6. MRI confirms brain metastasis, with at least one previously untreated intracranial brain parenchymal metastatic lesion with a longest diameter ≥1.0 cm;If the brain metastatic lesion has previously undergone radiotherapy, MRI is required.\n7. Confirm progression after radiotherapy;\n8. Provide sufficient fresh tissue specimens or tumor samples (primary lesion and\u002For metastatic lesions) ≥10 smears before treatment (preferably brain metastatic lesion specimens) for biomarker analysis.\n9. Use mannitol, hormones, or anticonvulsants before the first dose, but the drug treatment dose must be stable for at least one week without needing to be increased.Neurological symptoms stable for ≥1 week are required for enrollment.\n10. Organ function levels must meet the following requirements:\n\n1\\) Complete blood count:\n\n* ANC ≥1.5×10⁹\u002FL;\n* PLT ≥75×10⁹\u002FL;\n* Hb ≥90 g\u002FL (blood transfusion or drug treatment is allowed to ensure hemoglobin levels); 2) Coagulation function: INR ≤1.5, APTT ≤1.5×ULN; PT not exceeding the upper limit of normal.\n\n  3\\) Blood Biochemistry\n* TBIL ≤ 1.5 × ULN;\n* ALT and AST ≤ 3 × ULN (liver metastases ≤ 5.0 × ULN);\n* Cr ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault formula); 3) Echocardiography: LVEF ≥ 50%; 4) 12-lead ECG: Fridricia-corrected QT interval (QTcF) \\\u003C 470 ms for women and \\\u003C 450 ms for men; 10. Voluntary participation in this study, signing informed consent, good adherence, and willingness to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Leptomeningeal metastases or cystic metastases confirmed by MRI or lumbar puncture;\n2. Presence of third-space effusion (e.g., massive pleural effusion and ascites) that cannot be controlled by drainage or other methods;\n3. Received whole-brain radiotherapy, chemotherapy, or surgery within 2 weeks prior to treatment with the investigational drug, or received endocrine therapy within one week prior to treatment;\n4. Previous use of bevacizumab and PD-1\u002FPD-L1 inhibitors, excluding the following: no disease progression during bevacizumab and PD-1\u002FPD-L1 inhibitor use, investigators believe no drug resistance has been confirmed, and continued use would benefit the subject; short-term bevacizumab use to relieve cerebral edema;\n5. Participation in other drug clinical trials within 2 weeks prior to enrollment;\n6. Concurrent anti-tumor treatment for any other tumor;\n7. History of other malignancies within the past 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin;\n8. History of any heart disease, including: (1) arrhythmia requiring medication or of clinical significance; (2) myocardial infarction; (3) heart failure; (4) any other heart disease deemed unsuitable for participation in this trial by the investigator;\n9. A known history of allergy to any component of the medications in this regimen;\n10. A history of immunodeficiency, including a positive HIV test, active hepatitis B\u002FC, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;\n11. A history of a defined neurological or psychiatric disorder, including epilepsy or dementia;\n12. Pregnant or lactating women, women of childbearing age with a positive baseline pregnancy test, or patients who do not wish to use effective contraception throughout the trial;\n13. In the investigator's judgment, a serious comorbidity that would jeopardize patient safety or affect the patient's ability to complete the study (including but not limited to severe hypertension uncontrolled by medication, severe diabetes, active infection, thyroid disease, etc.);\n14. Any other circumstances deemed unsuitable for participation in this study by the investigator.",{"count":261,"type":22},58,[25],"This is an open-label, prospective, single-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin\u002Fcarboplatin, adebrelimab, and bevacizumab in patients with triple-negative breast cancer and brain metastases.",[265,266],"TNBC, Triple Negative Breast Cancer","Brain Metastasases",[268,269,270,271,272],"TNBC","brain metastatic","radiotherapy","Bevacizumab","adebrelimab","2026-06-16",{"date":218,"type":35},{"date":276,"type":35},"2026-02-02",{"date":278,"type":22},"2028-12-31",{"name":41,"class":42},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":286,"targetDuration":73,"studyType":74,"phases":4,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":43},"100641116","epidemiology-and-prognostic-analysis-of-chinese-cancer-patients-with-cancer-related-fatigue-100641116","NCT07656324","Epidemiology and Prognostic Analysis of Chinese Cancer Patients With Cancer-related Fatigue","Inclusion Criteria:\n\n1. Male or female, aged 18 years or older.\n2. Able to understand the purpose of this survey study, willing to participate, and able to sign an informed consent form.\n3. Malignant tumor confirmed histologically or cytologically.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. Patients with acute or chronic infections, or those with other serious medical conditions that, in the investigator's judgment, make them unsuitable for this study.\n3. Patients with two or more concurrent malignant tumors (excluding the following: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma).\n4. Patients with psychiatric illness or mental disorders, poor compliance, or who are unable to cooperate and report treatment responses.\n5. Patients with severe organic disease or major organ failure, such as decompensated heart, lung, liver, or kidney failure.\n6. Patients with other conditions that, in the investigator's opinion, make them unsuitable for participation in this study.",{"count":287,"type":22},1000000,"This investigator-initiated study aims to evaluate the incidence and severity of cancer-related fatigue (CRF) in patients with malignant tumors, to analyze the influencing factors of CRF, and to explore its impact on anti-tumor treatment and prognosis.",[125],[291,125],"Fatigue","2026-06-15",{"date":294,"type":35},"2026-06-18",{"date":296,"type":35},"2025-01-17",{"date":298,"type":22},"2027-01-17",{"name":41,"class":42},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":308,"targetDuration":309,"studyType":74,"phases":4,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":43},"100642141","a-phase-ii-observational-clinical-study-on-the-relationship-between-cerebrospinal-fluid-drug-concentration-and-efficacy-of-trastuzumab-deruxtecan-in-central-nervous-system-metastatic-breast-cancer-100642141","NCT07653893","A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer","A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration of Trastuzumab Deruxtecan and Efficacy in Central Nervous System Metastatic Breast Cancer","BCBM006","Inclusion Criteria:\n\n* 1\\. ≥18 years（2007-06）, any gender. 2. ECOG Performance Status 0-2. 3. Evidence of local recurrence or metastatic breast cancer not amenable to curative surgery or radiotherapy, and planned for intravenous trastuzumab deruxtecan treatment.\n\n  4\\. Expected survival time ≥8 weeks. 5. Provision of sufficient fresh tissue specimen or ≥10 unstained slides of tumor sample (primary and\u002For metastatic site) for biomarker analysis prior to treatment (intracranial metastatic lesion specimens preferred).\n\n  6\\. Cohort 2 (Experimental Cohort): Presence of brain parenchymal metastases confirmed by contrast-enhanced brain MRI, with at least one measurable brain lesion not previously irradiated, evaluable per RECIST 1.1 criteria.\n\n  7\\. Patients receiving mannitol, steroids, or anticonvulsant therapy prior to the first dose are eligible if the drug doses are stable for at least one week without requiring an increase, and neurological symptoms are stable for ≥1 week.\n\n  8\\. Organ function levels must meet the following requirements:\n  1. Hematology:\n\n     * ANC≥1.5×109\u002FL;\n     * PLT≥75×109\u002FL;\n     * Hb≥90 g\u002FL (allowing blood transfusion or medication to ensure hemoglobin content);\n  2. Coagulation function: APTT≤1.5×ULN；PT≤1.5×ULN;\n  3. Blood Chemistry:\n\n     • TBIL≤1.5×ULN;\n     * ALT and AST≤3×ULN (≤ 5.0×ULN for liver metastases);\n     * Creatinine ≤1.5 × ULN or Creatinine Clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula);\n  4. Cardiac Ultrasound: LVEF ≥50%;\n  5. 12-Lead ECG: Fridericia-corrected QT interval (QTcF) \\\u003C470 ms for females, \\\u003C450 ms for males; 9. Voluntary participation in this study, signed informed consent, good compliance, and willingness to cooperate with follow-up.\n\nExclusion Criteria:\n\n* 1\\. Presence of uncontrolled third-space fluid accumulation (e.g., large pleural effusion or ascites) not manageable by drainage or other methods, deemed unsuitable for enrollment by the investigator.\n\n  2\\. Previous treatment with an anti-HER2 ADC drug carrying the same payload resulting in resistance. Patients who discontinued prior ADC therapy for other reasons, including but not limited to toxicity, are eligible.\n\n  3\\. Adverse reactions from prior anti-tumor therapy have not recovered to ≤ Grade 1 per CTCAE v5.0 (except for ≤ Grade 2 toxicities judged by the investigator as having no safety risk, such as alopecia or long-term toxicities from radiotherapy).\n\n  4\\. History of other malignancies within the past 5 years, excluding cured carcinoma in situ of the cervix, basocellular skin carcinomas, or cutaneous squamous cell carcinoma.\n\n  5\\. History of severe cardiovascular or cerebrovascular diseases, including but not limited to:\n  * Severe cardiac rhythm or conduction abnormalities requiring clinical intervention, such as ventricular arrhythmia, II-III degree atrioventricular block, etc.\n  * Cardiac insufficiency of Class III\\~IV according to the New York Heart Association (NYHA) criteria.\n  * Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade 3 or higher cardiovascular\u002Fcerebrovascular events within 6 months prior to the first dose.\n  * Clinically uncontrolled hypertension.\n  * Any factors increasing the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, use of any concomitant medications known or suspected to prolong the QT interval; Known history of allergy to any component of the study drug.\n\n    6\\. History of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, history of organ transplantation, allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation.\n\n    7\\. HIV infection, active HBV or HCV infection. The following exceptions are allowed:\n  * Patients positive for hepatitis B surface antigen (HBsAg), with or without positive hepatitis B core antibody (anti-HBc), if HBV DNA \\\u003C 1000 IU\u002FmL or below the lower limit of detection at the research center, and per investigator assessment excluding active infection based on clinical treatment and presentation.\n  * Hepatitis C (HCV) antibody-positive patients who are HCV RNA-negative. 8. History of autoimmune diseases, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, or glomerulonephritis, except for autoimmune thyroid dysfunction treated with stable-dose hormone replacement therapy.\n\n    9\\. Patients with known idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, interstitial lung disease, severe radiation pneumonitis, or evidence of active pneumonia on screening chest CT scan.\n\n    10\\. Inability to cooperate with lumbar puncture. 11. Vaccination with any vaccine within 28 days prior to the first dose. 12. Pregnant or lactating female patients; female patients of childbearing potential with baseline pregnancy test positive; or patients unwilling to use effective contraception throughout the trial period.\n\n    13\\. Presence of any concomitant disease, per investigator judgment, that seriously endangers the patient's safety or affects the patient's ability to complete the study (including but not limited to severe hypertension that cannot be controlled by medication, severe diabetes, active infection, thyroid disease, etc.).\n\n    14\\. Any other circumstances where the researcher deems the patient unsuitable for participation in this study.",{"count":52,"type":22},"28 Days","Approximately 5-15% breast cancer patients develop brain metastases. Current local treatments (surgery\u002Fradiotherapy) are associated with significant complications, and systemic treatments have limited efficacy. Although new-generation ADC drugs, such as trastuzumab deruxtecan, have demonstrated breakthrough efficacy in patients with brain metastases, the mechanisms of action are not fully elucidated, moreover the current treatment regimens still have limitations for patients with HER2-low expressing, safer and more effective systemic treatment options are urgently needed to improve patient survival. BCBM-006 is an open-label, prospective, single-arm, single-center Phase II clinical study to evaluate the relationship between cerebrospinal fluid drug concentration and efficacy of trastuzumab deruxtecan in central nervous system metastatic breast cancer, and explore the incidence of leptomeningeal metastases diagnosed via lumbar puncture in patients with brain parenchymal metastases, facilitate early intervention to improve prognosis.",[312,56],"Central Nervous System (CNS) Metastases","2026-06-13",{"date":218,"type":35},{"date":316,"type":35},"2025-06-11",{"date":318,"type":22},"2028-06",{"name":41,"class":42},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":328,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":329,"targetDuration":73,"studyType":74,"phases":4,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":43},"100635820","opportunistic-breast-cancer-screening-using-non-contrast-chest-ct-100635820","NCT07557654","Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT","Artificial Intelligence-Assisted Opportunistic Screening for Breast Cancer Using Non-Contrast Chest CT: A Comparative Study With Mammography and\u002For Breast MRI","OPBCS-CT","Inclusion Criteria:\n\n1. Female patients who have undergone non-contrast chest CT examination;\n2. Participants included in the comparative analysis must have undergone at least one comparator imaging modality (mammography and\u002For breast MRI);\n3. If a breast lesion is detected, it must be confirmed by pathology or clinical follow-up at least 12 months;\n4. No prior systemic or local therapy before imaging examinations;\n5. Imaging data are complete and of sufficient quality for analysis.\n\nExclusion Criteria:\n\n1. History of other malignancies with potential impact on breast imaging interpretation;\n2. Participants with suspected malignant breast lesions but no confirmation;\n3. Prior radiotherapy, chemotherapy, or immunotherapy before imaging examinations;\n4. Imaging data that are incomplete, of poor quality, or contain significant artifacts preventing reliable analysis;\n5. Time interval between non-contrast chest CT and comparator imaging modalities exceeding three months, or with clinical events occurring between examinations that may alter lesion status.",true,{"count":330,"type":22},5000,"The goal of this observational study is to evaluate the feasibility and effectiveness of using non-contrast chest computed tomography scans for opportunistic breast cancer screening, and to further compare its diagnostic performance with conventional imaging modalities, including mammography and\u002For breast magnetic resonance imaging.",[56],[56,334,335,336,337,338],"Opportunistic Screening","Chest Computed Tomography","Mammography","Breast Magnetic Resonance Imaging","Artificial Intelligence","2026-06-11",{"date":292,"type":35},{"date":342,"type":35},"2026-05-06",{"date":344,"type":22},"2029-05-01",{"name":41,"class":42},{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":165,"enrollmentInfo":353,"targetDuration":4,"studyType":23,"phases":355,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":366,"locationsCount":43},"100643515","the-efficacy-of-compressionice-glovessocks-in-patients-with-utd1-induced-neuropathy-100643515","NCT07638774","The Efficacy of Compression\u002FIce Gloves\u002FSocks in Patients With UTD1-induced Neuropathy.","Reducing Peripheral Sensory and Motor Neuropathy Induced by UTD1 With Compression\u002FIce Gloves\u002FSocks, a Multi-center Prospective Phase III Trial (YBCSG-20-02).","Inclusion Criteria:\n\n1. Female ，18-75 years;\n2. Documentation of histologically or cytologically confirmed unresectable locally advanced or metastatic breast cancer;\n3. The participants is going to receive UTD1 based regimen at least 2 cycles；\n4. The baseline peripheral sensory neuropathy and peripheral motor neuropathy (CTCAE 5.0) is less than 1 grade;\n5. ECOG score ≤1;\n6. Adequate organ and bone marrow function defined as follows within 7 days before enrollment:\n\n   Absolute Neutrophil Count (ANC) ≥1,500\u002Fmm 3 (1.5 ×10 9\u002FL), white blood cell count (WBC) ≥3.5×10 9\u002FL, platelets ≥75,000\u002Fmm 3 (75×10 9\u002FL), hemoglobin ≥9 g\u002FdL (90 g\u002FL), no blood transfusion and blood products within 14 days, no G-CSF and other hematopoietic stimulation factor within 7 days.\n\n   Serum creatinine ≤1.5 × Upper Limit of Normal (ULN); AST, ALT, ALP exceeding the upper limit of normal but ≤ 2.5 × ULN when no liver metastasis; AST, ALT, ALP exceeding the upper limit of normal but ≤ 5 × ULN when liver metastasis.\n7. Expected survival time ≥12 weeks;\n8. No history of serious heart, lung, liver, kidney and other important organ diseases;\n9. Signed informed consent;\n10. Good compliance to the protocol;\n11. Women of childbearing age must already be using reliable contraception, a pregnancy test (blood or urine) is performed within 14 days before enrollment and the result was negative (if positive, pregnancy must be ruled out by ultrasound), and willing to use an appropriate methods of contraception during the trial and for 8 weeks after completion of the trial.\n\nExclusion Criteria:\n\n1. Previous treatment of UTD1;\n2. Severe uncontrolled infection.\n3. Patients with leptomeningeal metastases, symptomatic brain metastases, spinal cord compression, or brain or leptomeningeal disease detected on imaging at screening (patients who had completed local brain therapy 21 days before treatment and had stable symptoms and no cerebral hemorrhage confirmed by imaging were eligible).\n4. Patients whose hands\u002Ffeet are not suitable for wearing the compression\u002Fice gloves\u002Fsocks;\n5. Other conditions unsuitable for the enrollment, including but not limited to illiteracy, inability to complete the peripheral neurotoxicity scale, and other neurological abnormalities affecting the accurate assessment of neurotoxicity, etc.",{"count":354,"type":22},324,[356],"NA","This study is a prospective, multicenter, phase Ⅲ trial to evaluate of the compression\u002Fice gloves\u002Fsocks efficacy in UTD1-induced peripheral sensory and motor neuropathy. 324 patients will be included. All patients will be randomly divided into three groups at a ratio of 1:1:1. Group A is the blank control group, group B is the compression glove\u002Fsock group, and group C is the ice glove\u002Fsock group.",[359],"Locally Advanced or Metastatic Breast Cancer","2026-06-09",{"date":362,"type":35},"2026-06-10",{"date":364,"type":35},"2023-03-15",{"date":61,"type":22},{"name":41,"class":42},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":43},"100642419","phase-2-trastuzumab-deruxtecan-plus-ivonescimab-for-hormone-receptor-positive-her2-negative-advanced-breast-cancer-study-100642419","NCT07647016","Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study","A Prospective, Single-arm, Single-center Phase II Clinical Study of Deruxtecan in Combination With ivonescImab in Hormone Receptor-positive HER2 Negative Advanced Breast Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years, any gender.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n3. Histologically or cytologically confirmed Hormone Receptor-positive (HR+) and Human Epidermal Growth Factor Receptor 2 (HER2)-low or HER2-ultralow breast cancer, with evidence of locally recurrent or metastatic disease that is not amenable to curative-intent surgery or radiation therapy.\n\n   * HR positivity is defined as Estrogen Receptor (ER) positive (≥1% positive cells) and\u002For Progesterone Receptor (PR) positive (≥1% positive cells).\n   * HER2-low or HER2-ultralow expression is defined as HER2 (0 with staining), HER2 (1+), or HER2 (2+) by immunohistochemistry (IHC) with a negative in-situ hybridization (ISH) result.\n   * Fulfillment of these criteria from any single pathological assessment is sufficient for eligibility.\n4. Life expectancy of ≥ 3 months.\n5. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).\n6. History of recurrence or disease progression after prior treatment with a CDK4\u002F6 inhibitor (including in the adjuvant setting). Patients have received a maximum of one line of chemotherapy for recurrent or metastatic disease. Recurrence or disease progression during or within 6 months after completion of neoadjuvant\u002Fadjuvant intravenous chemotherapy is counted as one line of therapy.\n7. Patients with Central Nervous System (CNS) metastases are eligible. Ventriculoperitoneal shunt to relieve intracranial pressure or use of mannitol, corticosteroids, or anticonvulsants is permitted prior to the first dose. However, the dose of such medications must be stable for at least 1 week without an increase, and neurological symptoms must be stable without worsening for at least 1 week. (Priority will be given to the enrollment of patients with CNS metastases.)\n8. Availability of an adequate tumor tissue sample for retrospective analysis of PD-L1 status.\n9. Adequate organ function, defined as follows:\n\n   * Hematology: Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelets (PLT) ≥ 75 × 10⁹\u002FL; Hemoglobin (Hb) ≥ 90 g\u002FL (transfusion or medical support to meet this level is permitted).\n   * Hepatic and Renal Function: Total Bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 3 × ULN (≤ 5.0 × ULN in the presence of liver metastases); Blood Urea Nitrogen (BUN) or Serum Creatinine (Cr) ≤ 1.5 × ULN, or Creatinine Clearance ≥ 50 mL\u002Fmin (calculated by Cockcroft-Gault formula).\n   * Coagulation: Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN; Prothrombin Time (PT) ≤ 1.5 × ULN.\n   * Cardiac: QT interval corrected by Fridericia's formula (QTcF) \\\u003C 470 ms for females and \\\u003C 450 ms for males on a 12-lead electrocardiogram (ECG); Left Ventricular Ejection Fraction (LVEF) ≥ 50% by echocardiogram.\n10. Voluntary participation in the study with signed informed consent, and willingness to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Confirmed leptomeningeal metastases by Magnetic Resonance Imaging (MRI) or lumbar puncture.\n2. Prior treatment with anti-PD-1\u002FPD-L1 or anti-VEGF agents, unless both of the following conditions are met: (1) The patient did not experience disease progression during treatment with the anti-PD-1\u002FPD-L1 or anti-VEGF agent; and (2) The time from the last dose of the anti-PD-1\u002FPD-L1 or anti-VEGF agent to the time of recurrence or disease progression is ≥ 3 months.\n3. Presence of third-space fluid accumulation (e.g., massive pleural or peritoneal effusion) that cannot be controlled by drainage or other methods.\n4. Receipt of whole-brain radiotherapy, chemotherapy, targeted biologic therapy, immunotherapy, surgery, or endocrine therapy within 2 weeks prior to the first dose of study drug. Bone-modifying agents for the treatment of bone metastases or prevention of osteoporosis are permitted.\n5. Prior treatment with trastuzumab deruxtecan or any antibody-drug conjugate (ADC) containing a topoisomerase inhibitor.\n6. Participation in another interventional drug clinical trial within 2 weeks prior to enrollment. Participation in non-interventional studies is allowed.\n7. Major surgery or significant trauma within 4 weeks prior to randomization, or anticipation of the need for major surgery during the study.\n8. Concurrent receipt of any other anti-cancer therapy.\n9. History of other malignancies within the past 5 years, except for curatively treated cervical carcinoma in situ, cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and papillary thyroid carcinoma.\n10. History of any of the following cardiac conditions: (1) Myocardial infarction; (2) Congestive heart failure; (3) Any other cardiac condition judged by the investigator to be unsuitable for study participation.\n11. Known history of hypersensitivity to any component of the study drugs.\n12. History of immunodeficiency, including positive test for Human Immunodeficiency Virus (HIV), other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.\n13. Active hepatitis (Hepatitis B defined as HBsAg positive and HBV DNA ≥ 1000 IU\u002FmL; Hepatitis C defined as HCV antibody positive and HCV RNA \\> upper limit of normal).\n14. History of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required steroids, current ILD\u002Fpneumonitis, or suspected ILD\u002Fpneumonitis that cannot be ruled out by imaging at screening.\n15. Clinically significant pulmonary-specific comorbidities, including but not limited to any underlying pulmonary disease (e.g., pulmonary embolism within 3 months prior to the study, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.).\n16. Uncontrolled infection requiring systemic antibiotic, antiviral, or antifungal therapy.\n17. Clear history of neurological or psychiatric disorders, including epilepsy or dementia.\n18. Pregnant or breastfeeding women; women of childbearing potential with a positive pregnancy test at baseline or who are unwilling to use effective contraceptive measures throughout the study period.\n19. Presence of any concomitant disease that, in the investigator's judgment, could seriously compromise patient safety or interfere with completion of the study (including, but not limited to, uncontrolled severe hypertension, uncontrolled severe diabetes, active infection, etc.).\n20. Any other condition for which the investigator considers the patient unsuitable for participation in this study.",{"count":375,"type":22},53,[25],"The UNITY study is a prospective, single-arm, single-center, Phase II clinical trial conducted by Fudan University Shanghai Cancer Center. It aims to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) combined with ivonescimab in patients with hormone receptor-positive (HR+), HER2-negative recurrent or metastatic breast cancer.\n\nApproximately 53 patients will be enrolled. Eligible participants must have histologically confirmed advanced HR-positive breast cancer with HER2-low or HER2-ultralow expression. They must have experienced recurrence, metastasis, or disease progression after prior treatment with a CDK4\u002F6 inhibitor (including in the adjuvant setting) and have received at most one line of systemic chemotherapy for advanced disease. The study permits the enrollment of patients with central nervous system (CNS) metastases.\n\nThe primary endpoint is the Overall Response Rate (ORR). Key secondary endpoints include Clinical Benefit Rate (CBR), Overall Survival (OS), Progression-Free Survival (PFS), safety, and patient-reported quality of life (assessed using EORTC QLQ-C30 and QLQ-BR23). Exploratory endpoints will involve the analysis of biomarkers from tumor and blood samples, as well as PAM50 molecular subtyping and its correlation with survival outcomes.\n\nThis study seeks to explore the efficacy and safety of Trastuzumab Deruxtecan in combination with ivonescimab for patients with HR-positive, HER2-negative recurrent or metastatic breast cancer, with a particular focus on the subpopulation with CNS metastases.",[56],{"date":292,"type":35},{"date":381,"type":35},"2026-04-01",{"date":383,"type":22},"2028-02-01",{"name":41,"class":42},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":4},"100642169","phase-2-a-clinical-study-on-prophylactic-response-to-hetrombopag-for-secondary-prevention-in-anti-cancer-therapy-induced-thrombocytopeniae-100642169","NCT07647029","A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae","PROTECT","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Patients with histopathologically confirmed breast cancer;\n3. Receiving or expected to receive chemotherapy-based antitumor therapy with a cycle length of ≥21 days, and anticipated to receive ≥2 cycles of therapy;\n4. ECOG performance status 0-2;\n5. Platelet count meeting \\*\\*one\\*\\* of the following criteria:\n\n   1. Nadir platelet count \\\u003C 50×10⁹\u002FL in the previous antitumor treatment cycle;\n   2. Nadir platelet count ≥ 50×10⁹\u002FL but \\\u003C 75×10⁹\u002FL in the previous antitumor treatment cycle, accompanied by \\*\\*high risk factors for bleeding\\*\\*\\*;\n6. Platelet count ≥ 100×10⁹\u002FL at enrollment;\n7. Patients with breast cancer plus other malignancies are allowed, provided that the treatment plan is primarily for breast cancer;\n8. Adequate organ function:\n\n   * Bone marrow: ANC ≥ 1.5×10⁹\u002FL; hemoglobin ≥ 8 g\u002FdL;\n\n     * Hepatic and renal function: total bilirubin ≤ 1.5 × ULN; ALT, AST ≤ 2.5 × ULN (or ≤ 5 × ULN in the presence of liver metastasis); serum creatinine ≤ 1.5 × ULN or creatinine clearance \\> 60 mL\u002Fmin (Cockcroft-Gault formula);\n\n       * Coagulation: activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5 × ULN;\n9. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose, not be breastfeeding, and agree to use effective contraception during the study and for 7 days after the last dose of study drug.\n\n   Male subjects with female partners of childbearing potential must be surgically sterile or agree to use effective contraception during the study and for 7 days after the last dose of study drug; sperm donation is prohibited during the study;\n10. Life expectancy ≥ 3 months;\n11. Voluntarily participate in the study, sign the informed consent form, have good compliance, and be willing to comply with follow-up procedures.\n\n    * High risk factors for bleeding History of bleeding; prior treatment with platinum agents, gemcitabine, cytarabine, anthracyclines, PARP inhibitors (e.g., niraparib), etc.; combination of targeted agents and chemotherapeutic agents known to increase the risk of thrombocytopenia; history of radiotherapy or ongoing radiotherapy, especially to long bones and flat bones (e.g., pelvis, sternum).\n\nExclusion Criteria:\n\n1. Presence of hematological disorders, including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative neoplasms, multiple myeloma, and myelodysplastic syndromes;\n2. Uncontrolled active infection;\n3. History of arterial or venous thrombosis;\n4. Patients with bleeding tendency, or evidence of inherited bleeding diathesis or coagulation disorders;\n5. Pregnant or breastfeeding women, or female patients of childbearing potential not using effective contraception;\n6. Participation in another clinical trial of thrombopoietic agents within 4 weeks prior to enrollment;\n7. Presence of uncontrolled neurological or psychiatric disorders, poor compliance, or inability to cooperate and report treatment-related reactions;\n8. Bone marrow involvement;\n9. Administration of rhTPO or rhIL-11 within 7 days prior to enrollment;\n10. Hypersensitivity to the study drug(s).",{"count":393,"type":22},126,[25],"This study is a prospective clinical study enrolling breast cancer patients at high risk of chemotherapy-induced thrombocytopenia (CTIT). It aims to investigate the efficacy and safety of hetrombopag in the secondary prophylaxis of CTIT.\n\nBreast cancer patients with histologically or cytologically confirmed disease were enrolled after signing the informed consent form and were randomly assigned in a 1:1:1 ratio to three Arms. Stratification factors for randomization included the number of prior antineoplastic treatment cycles (\\>2 cycles vs. ≤2 cycles).\n\nArm 1: No prophylactic use of hetrombopag Arm 2: Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 of the first chemotherapy cycle (C1D1) continuously until the end of the second chemotherapy cycle Arm 3: Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 (C1D1) to Day 14 (C1D14) of the first chemotherapy cycle; the dosage and administration schedule in the second chemotherapy cycle were identical to those in the first cycle; Treatment continued until patients completed the protocol-specified treatment and follow-up, experienced intolerable toxicity, withdrew informed consent, initiated alternative antitumor therapy, died, or met any other treatment discontinuation criteria specified in the protocol, whichever occurred first.",[397],"Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)",[399,400,401,402],"Breast cancer","Secondary prophylaxis","Hetrombopag","Thrombocytopenia",{"date":292,"type":35},{"date":405,"type":22},"2026-05-28",{"date":407,"type":22},"2028-03-31",{"name":41,"class":42},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":43},"100464379","large-artery-occlusion-treated-in-extended-time-with-mechanical-thrombectomy-trial-100464379","NCT05326932","Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial","An Investigator Initiated and Conducted, Prospective, Multicenter, Randomized Outcome-blinded Study of Treating Mechanical Thrombectomy Exceeding 24 Hours in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion","LATE-MT","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Present 24-72 hours of stroke onset or last seen well\n3. Clinical diagnosis of AIS due to anterior circulation LVO (from internal carotid artery (ICA) extracranial segment to middle cerebral artery (MCA) M1 and M2 segment) on brain imaging\n4. National Institute of Health stroke scale (NIHSS) ≥6 at randomisation\n5. Viable cerebral tissue on computerized tomography perfusion (CTP) assessed: infarct core volume \\\u003C50 mL, mismatch ratio ≥1.8, and mismatch volume ≥15 mL\n6. Written informed consent (by patient or proxy, according to local requirements)\n\nExclusion Criteria:\n\nClinical Exclusion Criteria\n\n1. Considered unlikely to benefit from trial (e.g. advanced dementia, major pre-stroke disability (prior modified Rankins scale (mRS) ≥2), high likelihood of early death), as judged by the responsible treating clinician\n2. Major co-morbid disease that could interfere with outcome assessments and follow-up (e.g. cancer, severe heart failure, kidney failure)\n3. Pregnancy\n4. Unable to undergo a CTP\n5. Known allergy to iodine, heparin, anaesthesia, or other definite contraindication to receiving endovascular treatment (EVT) procedure\n6. Seizures at stroke onset or before randomization and baseline NIHSS scores cannot be accurately determined\n7. Baseline blood glucose of \\\u003C50 mg\u002FdL (2.78 mmol\u002FL) or \\>400 mg\u002FdL (22.20 mmol\u002FL)\n8. Baseline platelet count \\\u003C 50,000\u002FuL\n9. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with International normalized ratio (INR) \\>3\n10. Severe, sustained hypertension that can not be controlled by medication (systolic BP \\>220 mmHg or diastolic BP \\>120 mmHg)\n11. Presumed septic embolus, suspicion of bacterial endocarditis\n12. EVT attempted after stroke onset\n13. Unlikely to participate in follow-up assessments\n14. Currently participating in another trial that may affect outcomes.\n15. Any other condition that, in the opinion of the investigator will pose a significant hazard to the subject if participating in the trial.\n\nNeuroimaging Exclusion Criteria\n\n1. Intracranial hemorrhage (ICH), including parenchymal hemorrhage, ventricular hemorrhage, subarachnoid hemorrhage, and subdural\u002Fexsanguination\n2. Evidence of intracranial malignant tumor\n3. Significant mass effect with midline shift\n4. Aortic dissection\n5. Intracranial stent implanted in the same vascular territory\n6. Any other condition that may affect EVT procedure, like the tortuous vascular path the device is difficult to reach the target position or difficult to recover\n7. Occlusions in multiple vascular territories confirmed on Computerized tomography angiography (CTA)\u002F Magnetic resonance imaging angiography (MRA) (e.g. bilateral MCA occlusions, or an MCA and a basilar artery occlusion)",{"count":418,"type":22},336,[356],"A multi-center, prospective, randomized, open-label, adaptive group sequential designed, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS",[422],"Acute Ischemic Stroke",[424,425,426,427,428],"Acute ischemic stroke","Large vessel occlusion","Mechanical thrombectomy","Extended time","Randomised clinical trial",{"date":339,"type":35},{"date":431,"type":35},"2022-11-03",{"date":407,"type":22},{"name":41,"class":42},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":444,"briefSummary":446,"conditions":447,"keywords":450,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":460,"locationsCount":43},"100643016","phase-4-the-effects-of-different-anesthetics-on-the-brains-neural-networks-100643016","NCT07644663","The Effects of Different Anesthetics on the Brain's Neural Networks","Propofol, Dexmedetomidine, and Esketamine-Induced Unresponsive States: Alterations in Information Integration and Brain Networks","Inclusion Criteria:\n\n* Patients scheduled for elective non-cardiac surgery;\n* American Society of Anesthesiologists (ASA) physical status classification I-II;\n* Aged 18 to 65 years, regardless of gender;\n* Body mass index (BMI) greater than 18 kg\u002Fm² and no more than 31 kg\u002Fm²;\n* Written informed consent voluntarily signed by the patient or legal authorized representative for participation in this study.\n\nExclusion Criteria:\n\nSubjects meeting any one of the following items will be excluded from this study:\n\n* Presence of severe cardiovascular diseases or hepatic and renal insufficiency;\n* Hearing impairment;\n* History of psychiatric disorders or communication disorders;\n* Anticipated difficult airway;\n* Pregnant or lactating women;\n* History of allergic reaction or contraindication to any of the three anesthetic drugs used in this trial;\n* Participation in other clinical trials within the past 3 months.","65 Years",{"count":443,"type":22},120,[445],"PHASE4","This study aims to analyze the electroencephalographic power spectrum and connectivity during unresponsive states induced by propofol, esketamine and dexmedetomidine, respectively. It intends to explore the macro neural mechanisms underlying anesthetic unresponsiveness, so as to further elucidate the mechanisms by which anesthetics induce loss and recovery of consciousness. In addition, this study will identify neural biomarkers under general anesthesia for monitoring patients' actual intraoperative consciousness status. The findings will facilitate the development of monitoring indicators and devices reflecting intraoperative consciousness during general anesthesia, enabling more accurate assessment of patients' intraoperative consciousness status.",[448,449],"Electroencephalogram (EEG)","Anesthesia",[451,452,453],"EEG","anesthesia","loss of responsiveness","2026-06-08",{"date":456,"type":35},"2026-06-12",{"date":360,"type":22},{"date":459,"type":22},"2026-09-10",{"name":41,"class":42},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":17,"minAge":468,"maxAge":19,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":482,"leadSponsor":483,"locationsCount":43},"100631816","air-purifier-use-and-respiratory-health-in-copd-patients-100631816","NCT07505602","Air Purifier Use and Respiratory Health in COPD Patients","Respiratory Benefits of Indoor Air Purification in Patients With Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 50 and 80 years old\n* Physician diagnosis of COPD\n* Living in Shanghai during the intervention period\n* Subjects who have no plans to change homes during the intervention period\n* Non-smokers and former smokers\n\nExclusion Criteria:\n\n* Subjects living in a location other than home\n* Subjects with a history of alcohol abuse\n* Subjects with other chronic lung diseases, such as active tuberculosis, pulmonary fibrosis, cystic fibrosis, or alpha-1 antitrypsin deficiency\n* Subjects with a history of thoracic surgery\n* Subjects with a history of malignant tumors, such as lung cancer, liver cancer, or gastric cancer\n* Subjects with diagnosed chronic hepatic or renal insufficiency, such as liver cirrhosis, chronic viral hepatitis, or autoimmune liver disease\n* Subjects with acute myocardial infarction or unstable arrhythmia diagnosed within the past 6 weeks\n* Subjects currently participating in other interventional studies","50 Years",{"count":443,"type":22},[356],"This randomized, double-blind, parallel-controlled trial aims to evaluate the effects of an indoor air purifier intervention on respiratory health in patients with Chronic Obstructive Pulmonary Disease (COPD).",[473],"Respiratory Health",[475,476,477,478],"Chronic Obstructive Pulmonary Disease","Air purifier","Randomized controlled trial","Respiratory health","2026-06-05",{"date":360,"type":35},{"date":37,"type":35},{"date":61,"type":22},{"name":41,"class":42},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":43},"100637248","phase-3-sac-tmt-sequential-capecitabine-versus-capecitabine-in-early-stage-high-risk-triple-negative-breast-cancer-without-brca-mutations-100637248","NCT07628504","Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations","Sacituzumab Tirumotecan (Sac-TMT) Sequential Capecitabine Versus Capecitabine as Adjuvant Regimen for Triple-Negative Breast Cancer With Early-Stage, High-Risk, Non-BRCA Mutated Status: A Phase III, Randomized, Controlled, Open-Label, Multicenter Clinical Trial","STARTER","Inclusion Criteria:\n\n1. Female aged ≥ 18 years old.\n2. Diagnosis of operable primary invasive breast cancer.\n3. Negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), defined as follows: ER-negative is defined as \\\u003C10 % positive tumor cells by immunohistochemistry (IHC); PR-negative is defined as \\\u003C10 % positive tumor cells by IHC; HER2-negative is defined as IHC score of 0 or 1+, or IHC score of 2+ with negative (non-amplified) results confirmed by fluorescence in situ hybridization (FISH) or chromogenic in situ hybridization (CISH).\n4. Non-mutated for BRCA1\u002F2 genes.\n5. Patients must satisfy any one of the following conditions:\n\n   1. Baseline clinical lymph node-positive (cLN+) or pathological lymph node-positive (pN+) status with non-pathological complete response (non-pCR), who have completed adequate neoadjuvant therapy (at least 6 cycles of chemotherapy containing anthracycline and\u002For taxane, with or without PD-1 inhibitor immunotherapy).\n   2. Pathological lymph node-positive (pN+) status without prior neoadjuvant therapy, who have undergone adequate surgery, adjuvant chemotherapy (at least 6 cycles of taxane- and\u002For anthracycline-containing regimen with or without carboplatin), and adjuvant radiotherapy (if applicable).\n6. No evidence of distant metastasis shown by imaging examinations performed within 3 months prior to randomization.\n7. Adequate organ and bone marrow function.\n8. Acute toxicities from any prior therapy have recovered to baseline levels or resolved to Grade ≤ 1 per NCI CTCAE Version 5.0 (excluding adverse events deemed non-safety risks at the investigator's discretion).\n9. Post-menopausal status or documented non-childbearing potential. For women of childbearing potential, urine pregnancy tests must be negative at post-surgery screening and baseline visits. All participants and their male partners of childbearing potential must use effective medical contraception from the date of informed consent signature until 6 months after the last dose of study treatment.\n10. Voluntarily participate in the study, provide written informed consent, and be able to comply with protocol-specified visits and procedures.\n\nExclusion Criteria:\n\n1. Patients with Stage T4 disease, including those with inflammatory breast cancer;\n2. Patients with Stage N3 disease;\n3. Patients with positive supraclavicular or internal mammary lymph nodes;\n4. Previous history of breast cancer;\n5. Significant cardiovascular diseases such as baseline left ventricular ejection fraction (LVEF) \\\u003C 50% assessed by echocardiography (ECHO) or multigated acquisition (MUGA) scan at screening, or New York Heart Association (NYHA) Class III or IV cardiomyopathy;\n6. Prior treatment with TROP2-targeted therapy and\u002For topoisomerase I inhibitors;\n7. History of other malignant neoplasms within the past 5 years, excluding cured carcinoma in situ of the cervix, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma;\n8. Known hypersensitivity to study drugs and their components, history of immunodeficiency, or history of organ transplantation;\n9. History of non-infectious interstitial lung disease (ILD) or non-infectious pneumonia requiring steroid therapy, current ILD or non-infectious pneumonia, or suspected ILD\u002Fnon-infectious pneumonia that cannot be ruled out by imaging at screening; clinically significant severe pulmonary impairment secondary to concomitant pulmonary diseases, including but not limited to any underlying pulmonary disorders (e.g., pulmonary embolism within 3 months prior to first dose, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion) or any autoimmune, connective tissue, or inflammatory diseases potentially involving the lungs (i.e., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis), or prior pneumonectomy;\n10. Documented severe dry eye syndrome, severe meibomian gland disease and\u002For blepharitis, or history of corneal disorders that hinder delayed corneal healing;\n11. Active autoimmune diseases requiring systemic therapy within the past 2 years (hormone replacement therapy is not considered systemic therapy, e.g., type 1 diabetes mellitus, hypothyroidism managed with thyroid hormone replacement only, adrenal or pituitary insufficiency managed with physiological-dose glucocorticoid replacement only);\n12. Active infections requiring systemic therapy within 2 weeks prior to the first dose;\n13. Patients with malabsorption syndromes affecting glucuronosyltransferase (Gl) function, history of gastric or small bowel resection, or inability to swallow capecitabine tablets;\n14. Concomitant severe diseases that jeopardize patient safety or interfere with study completion as judged by the investigator, including but not limited to uncontrolled hypertension, severe diabetes mellitus, and active infections;\n15. Any other conditions rendering the patient ineligible for study participation in the investigator's opinion.",{"count":493,"type":22},420,[190],"The goal of this clinical trial is to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT) sequential capecitabine versus single-agent capecitabine as adjuvant intensified therapy in patients with high-risk early-stage triple-negative breast cancer (TNBC) without BRCA mutations.\n\nThe main questions it aims to answer are:\n\n1. Does sacituzumab tirumotecan (sac-TMT) sequential capecitabine improve survival outcomes compared with capecitabine monotherapy in this patient population?\n2. What is the safety profile of sacituzumab tirumotecan (sac-TMT)-containing adjuvant therapy versus capecitabine monotherapy? Researchers will compare the sacituzumab tirumotecan (sac-TMT)-sequential-capecitabine experimental arm with the capecitabine-alone control arm to see if the experimental regimen provides superior adjuvant anti-tumor efficacy with acceptable safety.\n\nParticipants will be randomized in a 1:1 to Receive assigned study treatment as follows:\n\nExperimental arm: Sacituzumab tirumotecan (sac-TMT) 4 mg\u002Fkg intravenously on Day 1 of each 3-week cycle for 8 cycles, followed by sequential capecitabine at stratified doses; patients with prior PD-1\u002FL1 inhibitor exposure will continue PD-1\u002FL1 inhibitor therapy for up to 1 year Control arm: Capecitabine monotherapy at stratified doses; patients with prior PD-1\u002FL1 inhibitor exposure will continue PD-1\u002FL1 inhibitor therapy for up to 1 year",[497],"Adjuvant Drug Therapy","2026-06-04",{"date":479,"type":35},{"date":501,"type":22},"2026-05-18",{"date":503,"type":22},"2035-03-30",{"name":41,"class":42},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":328,"sex":17,"minAge":512,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":521,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":4},"100638461","ai-empowered-nudge-to-improve-colonoscopy-uptake-ainc-100638461","NCT07612436","AI-empowered Nudge to Improve Colonoscopy Uptake (AINC)","AI-empowered Nudge to Improve Colonoscopy Uptake (AINC): A Pragmatic Cluster-Randomized Trial","Inclusion Criteria:\n\n* Aged 45-74 years;\n* Test positive on the Colorectal Cancer Risk Assessment Scale and the immunochemical fecal occult blood test;\n* In good general health, mentally competent;\n* Provide informed consent.\n\nExclusion Criteria:\n\n* History of colorectal resection;\n* Previous diagnosis of cancer or currently undergoing any cancer-related treatment;\n* Underwent a colonoscopy or sigmoidoscopy within the past 5 years;\n* Contraindications to colonoscopy (e.g. severe cardiac, cerebral, lung diseases, or renal dysfunction).","45 Years","74 Years",{"count":515,"type":22},1680,[356],"Colorectal cancer (CRC) ranks third in both incidence and mortality among all malignant tumors in China. Studies have shown that early screening can significantly reduce its incidence and mortality. Colonoscopy is the gold standard for CRC screening; however, compliance with colonoscopy among high-risk groups in China is very low. Artificial intelligence (AI)-assisted tools can provide real-time, personalized health education, and nudge strategies can help translate intent into action. This trial aims to evaluate the effectiveness of AI-empowered nudge for improving colonoscopy uptake among high-risk individuals aged 45 to 74 in China. It's a two-arm, pragmatic cluster randomized controlled trial. The main question it aims to answer is whether the AI-enabled personalized health education and nudge strategies improve colonoscopy adherence.\n\nParticipants will:\n\n1. Be recruited and allocated into one of two groups according to the assigned clusters. Participants in one group will be invited to receive usual care. In addition to usual care, participants in the other group will receive AI-empowered nudge, featuring an AI chatbot providing real-time personalized responses and a nudge environment with default screening option.\n2. Have their colonoscopy status checked at the end of trial.",[519,520],"Colorectal Neoplasms","Colonoscopy",[522,523,524,525,526,527],"Colorectal cancer","artificial intelligence","screening adherence","randomized controlled trial","nudge","Behavioral intervention","2026-06-03",{"date":498,"type":35},{"date":531,"type":22},"2026-05-30",{"date":533,"type":22},"2027-12-31",{"name":41,"class":42},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":512,"enrollmentInfo":542,"targetDuration":4,"studyType":23,"phases":544,"briefSummary":545,"conditions":546,"keywords":548,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":43},"100586355","phase-2-tqb2450-plus-progestin-for-fertility-sparing-treatment-in-mmrd-ec-100586355","NCT06914297","TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC","Immune Checkpoint Inhibitors Combined With Progestins for Fertility-sparing Treatment in Patients With MMRd Endometrial Cancer: a Multicenter Single-arm Prospective Clinical Trial","Inclusion Criteria:\n\n1. Age range from 18 to 45 years.\n2. Pathological diagnosis of endometrioid carcinoma by biopsy, diagnostic curettage or hysteroscopy, non-invasive (G1-2); clinical diagnosis by G1-2); clinical diagnosis confirmed by at least two associate senior physicians;\n3. Run possible, unknown EC;\n4. Intense MRI, enhanced MMRI, enhanced MRI\u002FCT, and pulmonary CT, or PET\u002FCT assessments indicated that the lesions were limited to the endometrial layer or superficial myometrium, and there was no clear deep myometrium, cervix, or extrauterine involvement.\n5. , WHFIGO 2023 IA1-IA2;\n6. EC molecular typing, resulting in MMRd type (molecular typing is based on the World Health Organization (WHO) classification criteria for female genital tumors (5th edition) );\n7. Those who require or insist on preserving reproductive function, or those who insist on preserving the uterus despite having no fertility requirements.\n\n   informed\n8. The hospital was followed up on schedule. 2. Exclusion criteria\n9. and can be followed up regularly in this hospital.\n\nExclusion Criteria:\n\n1. Endometrioid carcinoma FIGO grade G3, type II EC (including serous carcinoma, clear cell carcinoma, carcinosarcoma, undifferentiated carcinoma, dedifferentiated carcinoma, neuroendocrine carcinoma, etc.), or other non-epithelial uterine malignancies (adenosarcoma, stromal sarcoma, etc.);\n2. Imaging evaluation indicates deep myometrial involvement, cervical involvement, or the possibility of extrauterine metastases.\n3. History of important organ transplantation;\n4. Uncontrolled diseases or active infections;\n5. Concomitant with severe acute diseases such as stroke, myocardial infarction, etc.\n6. Other malignant tumors of the reproductive system (except in patients with Lynch syndrome who also have ovarian cancer).\n7. Those who require hysterectomy or other methods of treatment other than conservative medication.\n8. Pregnant persons;\n9. Those who have received conservative treatment (or medication maintenance treatment) with high-potency progesterone or oral contraceptives for more than 1 month due to endometrial hyperplasia in the past three months;\n10. Smoking history, those who smoke more than 15 cigarettes per day;\n11. Those who are contraindicated in the use of immunosuppressants or progesterone.",{"count":543,"type":22},10,[25],"Based on the above situation, the investigators propose the following scientific hypothesis: In young patients with early MMRd type EC, the use of immune checkpoint inhibitors combined with progesterone for fertility retention therapy can improve the therapeutic efficacy, reduce recurrence, and improve tumor prognosis.\n\nBased on the above assumptions, this project intends to conduct a prospective exploratory clinical study in EC patients limited to the endometrial layer or superficial myometrium (FIGO 2023 IA1-IA2 stage). The subjects were treated with TQB2450 periodic intravenous drip + high-potency progesterone daily oral therapy. During the treatment period, hysteroscopy was performed every 12 weeks to evaluate the therapeutic efficacy. The primary endpoint was the 12-week CR rate; the secondary endpoints included the 24-week CR rate, the 36-week CR rate, the median CR time, the 1-year relapse rate, the 2-year relapse rate, the median relapse time, the pregnancy rate, the live birth rate, and drug-related adverse reactions. The exploratory indicators were the response of different MMRd tumors to immune checkpoint inhibitors and their possible mechanisms. The development of this study will provide a clinical basis for improving the fertility-preserving treatment regimen of MMRd EC.",[547],"Endometrial Cancer",[549,550,551,552],"endometrial cancer","Immune checkpoint inhibitor","fertility-sparing treatment","dMMR",{"date":498,"type":35},{"date":555,"type":35},"2025-04-21",{"date":557,"type":22},"2029-04-01",{"name":41,"class":42},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":328,"sex":50,"minAge":18,"maxAge":512,"enrollmentInfo":566,"targetDuration":4,"studyType":23,"phases":568,"briefSummary":569,"conditions":570,"keywords":572,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":43},"100458257","phase-2-gonadotropin-releasing-hormone-agonist-gnrha-plus-letrozole-in-young-women-with-early-endometrial-cancer-100458257","NCT05247268","Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer","Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer","Inclusion Criteria:\n\n* Consent informed and signed\n* Primarily have a confirmed diagnosis of early-stage endometrial cancer (endometrioid, grade I, without myometrial inva- sion) ) based upon endometrial biopsy, diagnostic curettage or hysteroscopy\n* No signs of suspicious myometrial invasion or extrauterine metastasis by enhanced magnetic resonance imaging (MRI), enhanced computed tomography (CT) or transvaginal ultrasonography (TVUS)\n* Have a strong desire for remaining reproductive function or uterus\n* Have good compliance and follow-up conditions, and patients are willing to follow up in Obstetrics and Gynecology Hospital of Fudan University in time\n\nExclusion Criteria:\n\n* Pathologically confirmed as endometrial cancer with suspicious myometrial invasion or extrauterine metastasis\n* Recurrent endometrial cancer\n* Combined with severe medical disease or severely impaired liver and kidney function\n* Patients with other types of endometrial cancer or other malignant tumors of the reproductive system; patients with breast cancer or other hormone- dependent tumors that cannot be used with progesterone\n* Those who require hysterectomy or other methods other than conservative treatment with drugs\n* Known or suspected pregnancy\n* Contraindication for Medroxyprogesterone Acetate, Megestrol Acetate, Triprorelin Acetate, Letrozole or pregnancy\n* Hormone treatment within 3 months before entering the trial;\n* Acute severe disease such as stroke or heart infarction or a history of thrombosis disease\n* Smoker(\\>15 cigarettes a day)",{"count":567,"type":22},104,[25],"To see if Gonadotropin-releasing hormone analogue (GnRHa) combined with aromatase inhibitors (AIs) will achieve better complete response rate than megestrol acetate or medroxyprogesterone acetate (MA\u002FMPA) alone as fertility-sparing treatment for patients with early endometrial carcinoma.",[571],"Endometrial Neoplasm Malignant Stage I",[573,574,575,576],"early endometrial carcinoma","fertility-preserving treatment","gonadotropin-releasing hormone analogue","aromatase inhibitors",{"date":498,"type":35},{"date":579,"type":35},"2022-03-11",{"date":581,"type":22},"2027-09-10",{"name":41,"class":42},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":590,"targetDuration":592,"studyType":74,"phases":4,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":43},"100640074","association-between-screening-behaviors-and-lung-cancer-spectrum-100640074","NCT07626177","Association Between Screening Behaviors and Lung Cancer Spectrum","A Multicenter, Prospective, Observational Study on the Association Between Real-World Lung Cancer Screening Behaviors and Lung Cancer Disease Spectrum","Inclusion Criteria:\n\n* Histologically confirmed primary lung cancer within the past year (surgical or biopsy pathology).\n* Patients capable of clearly recalling or providing medical and physical examination history prior to diagnosis.\n\nExclusion Criteria:\n\n* Recurrent lung cancer or metastatic lung tumors.\n* Severe lack of critical clinical data (e.g., inability to provide pathological type or stage).\n* Patients with cognitive impairment or severe mental illness who cannot cooperate with the questionnaire.",{"count":591,"type":22},5390,"1 Month","The goal of this observational study is to describe the clinical epidemiological characteristics and disease spectrum distribution of newly diagnosed primary lung cancer patients in a real-world setting. The main questions it aims to answer are:\n\nWhat is the current status of lung cancer epidemiology, including age, gender, smoking history, and pathological subtype distribution? How do different lung cancer screening behaviors (e.g., overscreening, underscreening, guideline-concordant, and precision screening) influence the capture rate of the \"curative time window\" (defined as adenocarcinoma in situ (AIS)\u002Fminimally invasive adenocarcinoma (MIA) or pure Ground-Glass Nodules (GGNs) stage)? What are the economic costs and cumulative radiation exposure associated with these different screening patterns? Researchers will compare these screening behavior groups to evaluate the efficacy of the \"low-age, low-frequency\" screening strategy in capturing early-stage lung cancer.\n\nParticipants will be asked to:\n\nProvide their medical history and detailed records of pre-diagnosis lung cancer screening (including CT scan history).\n\nAllow researchers to collect and analyze their clinical, pathological, and radiological data from hospital records and medical databases.\n\nComplete a questionnaire regarding their screening history and health-related behaviors.",[595],"Lung Cancer",{"date":498,"type":35},{"date":598,"type":35},"2026-05-14",{"date":600,"type":22},"2027-06-01",{"name":41,"class":42},""]